CA2685349A1 - Temperature-controlled and ph-dependant self-gelling biopolymeric aqueous solution - Google Patents
Temperature-controlled and ph-dependant self-gelling biopolymeric aqueous solution Download PDFInfo
- Publication number
- CA2685349A1 CA2685349A1 CA2685349A CA2685349A CA2685349A1 CA 2685349 A1 CA2685349 A1 CA 2685349A1 CA 2685349 A CA2685349 A CA 2685349A CA 2685349 A CA2685349 A CA 2685349A CA 2685349 A1 CA2685349 A1 CA 2685349A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- acid
- polymer
- composition according
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/26—Mixtures of macromolecular compounds
Abstract
The present invention relates a biopolymeric liquid aqueous composition for producing self-gelling systems and gels, which comprises: an acidic water-based medium, 0.1 to 10% by weight of a pH-gelling acid-soluble biopolymer; and 0.1 to 10% by weight of a water-soluble molecule having a basic character and a pKa between 6.0 and 8.4, or a water-soluble residue or sequence of the molecule having a basic character and a pKa between 6.0 and 8.4. The liquid composition has a final pH ranging from 5.8 and 7.4, and forms a stable solid and homogeneous gel within a temperature range from to 70°C. The present invention also relates to a method for preparing the composition and uses thereof.
Description
TEMPERATURE-CONTROLLED AND PH-DEPENDANT SELF-GELLING BIOPOLYMERIC AQUEOUS
SOLUTION
BACKGROUND OF THE INVENTION
(a) Field of the Invention The present invention relates to the composition of molecular assemblies in liquid solution that enables temperature-controlled pH-dependant formation of biopolymeric gels, such as polysaccharide-based, and methods of preparation thereof.
(b) Description of Prior Art Biopolymers and macromolecules are attractive materials for the preparation and design of self-gelling and/or auto-assembling systems.
Numerous attempts tend to develop such systems on the basis of polysaccharides and polypeptides.
In situ formed gels were also proposed with ionic polysaccharides. A composition can be used as a medical device for drug delivery, the application of a diagnostic agent, or the prevention of post-operative adhesions, and is composed of an aqueous liquid vehicle which is capable of being gelled in situ. It includes at least one ionic polysaccharide, at least one film forming polymer, and a medicament or pharmaceutical agent, water, and optionally, a counter-ion capable of gelating the ionic polysaccharide. However, the gelation is reached by interaction between the ionic polysaccharide and the film-forming polymer, or by counter-ion induced cross-linking of the ionic polysaccharide. Other in situ forming gels are based upon polyoxyalkylene composition or polyoxyalkylene/ polysaccharide mixture or alginate/cation mixture in situ.
It would be highly desirable to be provided with a biopolymeric gel that is formed while excluding any organic solvent, any organic monomers, any ionic or covalent cross-linking that may be potentially toxic or induce a reduced biological compatibility.
It would be highly desirable to be provided with a biopolymeric gel that is formed by stimulus-induced free interactions between biologically acceptable and well-recognized molecules.
It would be highly desirable to be provided with, a temperature-controlled pH-dependant formed biopolymeric gels that could be used to
SOLUTION
BACKGROUND OF THE INVENTION
(a) Field of the Invention The present invention relates to the composition of molecular assemblies in liquid solution that enables temperature-controlled pH-dependant formation of biopolymeric gels, such as polysaccharide-based, and methods of preparation thereof.
(b) Description of Prior Art Biopolymers and macromolecules are attractive materials for the preparation and design of self-gelling and/or auto-assembling systems.
Numerous attempts tend to develop such systems on the basis of polysaccharides and polypeptides.
In situ formed gels were also proposed with ionic polysaccharides. A composition can be used as a medical device for drug delivery, the application of a diagnostic agent, or the prevention of post-operative adhesions, and is composed of an aqueous liquid vehicle which is capable of being gelled in situ. It includes at least one ionic polysaccharide, at least one film forming polymer, and a medicament or pharmaceutical agent, water, and optionally, a counter-ion capable of gelating the ionic polysaccharide. However, the gelation is reached by interaction between the ionic polysaccharide and the film-forming polymer, or by counter-ion induced cross-linking of the ionic polysaccharide. Other in situ forming gels are based upon polyoxyalkylene composition or polyoxyalkylene/ polysaccharide mixture or alginate/cation mixture in situ.
It would be highly desirable to be provided with a biopolymeric gel that is formed while excluding any organic solvent, any organic monomers, any ionic or covalent cross-linking that may be potentially toxic or induce a reduced biological compatibility.
It would be highly desirable to be provided with a biopolymeric gel that is formed by stimulus-induced free interactions between biologically acceptable and well-recognized molecules.
It would be highly desirable to be provided with, a temperature-controlled pH-dependant formed biopolymeric gels that could be used to
-2-encapsulate cells and cellular material while retaining their biological activity.
It would be highly desirable to be provided with such gels, which would retain its solid or gel state at the physiological temperature or 37 C.
SUMMARY OF THE INVENTION
One aim of the present invention is to provide a way allowing the preparation of a neutral clear liquid solution of a pH-controlled acid-soluble biopolymer while avoiding any unwanted precipitation or heterogeneous gelation.
A second major aim of the present invention is to provide a neutral clear liquid solution of a pH-controlled acid-soluble biopolymer that will thermally form solid homogeneous gels at a temperature close to the physiological temperature.
Another aim is to provide temperature-controlled pH-dependant formed gels, which could be used to encapsulate cells and cellular material while retaining their biological activity.
A further aim of the present invention is to provide gels that would retain its solid or gel state at the physiological temperature or 37 C.
Still one aim of the present invention is to provide a method for the preparation of such gels.
In accordance with the present invention, there is provided a biopolymeric liquid aqueous composition for producing self-gelling systems and gels, which comprises:
a) an acidic water-based medium; and b) 0.1 to 10% by weight of a pH-gelling acid-soluble biopolymer;
and c) 0.1 to 10% by weight of a water-soluble molecule having a basic character and a pKa between 6.0 and 8.4, or a water-soluble residue or sequence of the molecule having a basic character and a pKa between 6.0 and 8.4;
wherein the liquid composition has a final pH ranging from 5.8 and 7.4, and forms a stable solid and homogeneous gel within a temperature range from 10 to 70 C.
It would be highly desirable to be provided with such gels, which would retain its solid or gel state at the physiological temperature or 37 C.
SUMMARY OF THE INVENTION
One aim of the present invention is to provide a way allowing the preparation of a neutral clear liquid solution of a pH-controlled acid-soluble biopolymer while avoiding any unwanted precipitation or heterogeneous gelation.
A second major aim of the present invention is to provide a neutral clear liquid solution of a pH-controlled acid-soluble biopolymer that will thermally form solid homogeneous gels at a temperature close to the physiological temperature.
Another aim is to provide temperature-controlled pH-dependant formed gels, which could be used to encapsulate cells and cellular material while retaining their biological activity.
A further aim of the present invention is to provide gels that would retain its solid or gel state at the physiological temperature or 37 C.
Still one aim of the present invention is to provide a method for the preparation of such gels.
In accordance with the present invention, there is provided a biopolymeric liquid aqueous composition for producing self-gelling systems and gels, which comprises:
a) an acidic water-based medium; and b) 0.1 to 10% by weight of a pH-gelling acid-soluble biopolymer;
and c) 0.1 to 10% by weight of a water-soluble molecule having a basic character and a pKa between 6.0 and 8.4, or a water-soluble residue or sequence of the molecule having a basic character and a pKa between 6.0 and 8.4;
wherein the liquid composition has a final pH ranging from 5.8 and 7.4, and forms a stable solid and homogeneous gel within a temperature range from 10 to 70 C.
-3-The composition can be prepared from organic and/or inorganic acids, such as hydrochloric acid, citric acid, ascorbic acid, lactic acid, lactobionic acid, acetic acid, salicylic acid, formic acid, glutamic acid, . phosphoric acid, orthophosphoric acid, or glycerophosphoric acid, or a mixture thereof.
The biopolymer preferably comprises a pH-gelling acid-soluble polysaccharide, polypeptidic or poly(amino acids), or synthetic polymer, such as a solution of chitosan, modified chitosan or chitosan derivative, the solution of chitosan being cationic and bearing amino groups.
The molecule, residue or sequence may be an organic salt selected from the group consisting of mono-phosphate salt, mono-sulfonate salt, mono-sulfate salt and mono-carboxylate salt.
Alternatively, the molecule, residue or sequence may be a salt of polyol selected from the group consisting of mono-phosphate dibasic salt, mono-sulfonate salt, mono-sulfate salt and mono-carboxylate salt of polyol, said polyol being selected from the group consisting of glycerol, histidinol, acetol, diethylstil-bestrol, indole-glycerol, sorbitol, ribitol, xylitol, arabinitol, erythritol, inositol, mannitol, glucitol, palmitoyl-glycerol, linoleoyl-glycerol, oleoyl-glycerol, and arachidonoyl-glycerol, or a mixture thereof.
The glycerol may also be selected from the group consisting of glycerol-2-phosphate, sn-glycerol 3-phosphate and L-glycerol-3-phosphate salt, or a mixture thereof.
In a further embodiment, the molecule, residue or sequence is a salt of a sugar selected from the group consisting of mono-phosphate dibasic salt, mono-sulfonate salt, mono-sulfate salt and mono-carboxylate salt of a sugar, said sugar being selected from the group consisting of fructose, galactose, ribose, glucose, xylose, rhamnulose, sorbose, erythrulose, deoxy-ribose, ketose, mannose, arabinose, fuculose, fructopyranose, ketoglucose, sedoheptulose, trehalose, tagatose, sucrose, allose, threose, xylulose, hexose, methylthio-ribose, and methylthio-deoxy-ribulose, or a mixture thereof.
The molecule, residue or sequence may be selected from the group consisting of sodium, magnesium or iron salt of glycerol-2-phos-phate, sn-glycerol-3-phosphate and L-glycerol-3-phosphate, glucose-l-
The biopolymer preferably comprises a pH-gelling acid-soluble polysaccharide, polypeptidic or poly(amino acids), or synthetic polymer, such as a solution of chitosan, modified chitosan or chitosan derivative, the solution of chitosan being cationic and bearing amino groups.
The molecule, residue or sequence may be an organic salt selected from the group consisting of mono-phosphate salt, mono-sulfonate salt, mono-sulfate salt and mono-carboxylate salt.
Alternatively, the molecule, residue or sequence may be a salt of polyol selected from the group consisting of mono-phosphate dibasic salt, mono-sulfonate salt, mono-sulfate salt and mono-carboxylate salt of polyol, said polyol being selected from the group consisting of glycerol, histidinol, acetol, diethylstil-bestrol, indole-glycerol, sorbitol, ribitol, xylitol, arabinitol, erythritol, inositol, mannitol, glucitol, palmitoyl-glycerol, linoleoyl-glycerol, oleoyl-glycerol, and arachidonoyl-glycerol, or a mixture thereof.
The glycerol may also be selected from the group consisting of glycerol-2-phosphate, sn-glycerol 3-phosphate and L-glycerol-3-phosphate salt, or a mixture thereof.
In a further embodiment, the molecule, residue or sequence is a salt of a sugar selected from the group consisting of mono-phosphate dibasic salt, mono-sulfonate salt, mono-sulfate salt and mono-carboxylate salt of a sugar, said sugar being selected from the group consisting of fructose, galactose, ribose, glucose, xylose, rhamnulose, sorbose, erythrulose, deoxy-ribose, ketose, mannose, arabinose, fuculose, fructopyranose, ketoglucose, sedoheptulose, trehalose, tagatose, sucrose, allose, threose, xylulose, hexose, methylthio-ribose, and methylthio-deoxy-ribulose, or a mixture thereof.
The molecule, residue or sequence may be selected from the group consisting of sodium, magnesium or iron salt of glycerol-2-phos-phate, sn-glycerol-3-phosphate and L-glycerol-3-phosphate, glucose-l-
-4-phosphate, glucose-6-phosphate, fructose-l-phosphate and fructose-6-phosphate, or a mixture thereof.
The molecule, residue or sequence is preferably a sodium, magnesium or iron salt selected from the group consisting of N-[carbamoy[methyl]-2-aminoethane sulfonate (ACES), N,N-bis[2-hydroxyethyl]-2-aminoethane sulfonate (BES), 3-[N,N-bis(2-hydroxy-ethyl)amino]-2-hydroxypropanesulfonate (DIPSO), N-[2-hydroxyethyl]piperazine-N'-3-propane-sulfonate (EPPS), N-[2-hydroxyethyl]piperazine-N'-4-butane-sulfonate (HEPBS), N-[2-hydroxyethyl]piperazine-N'-3-propanesu-fonate (HEPES), N-[2-hydroxyethyl] piperazine-N'-2-hydroxypropanesulfonate (HEPSO), 2-[N-morpholino]ethanesulfonate (MES), 4-[N-morpholino]butanesulfonate (MOBS), 3-[N-morpholino]butanesulfonate (MOPS), 3-[N-morpholino]-2-hydroxypropanesulfonate (MOPSO), Piperazine-N,N'-bis[2-ethanesulfonate] (PIPES), Piperazine-N,N'-bis[2-hydroxypropanesulfonate]
(POPSO), 3-[N-tris(hydroxymethyl)methylamino]-2-hydroxypropanesulfonate (TAPSO), and N-tris [hydroxymethyl]methyl-2-minoethanesulfonate(TES), and derivatives or mixtures thereof.
The molecule, residue or sequence is preferably selected from the group consisting of N,N-bis[hydroxyethyl]glycine (BICINE), bis [2-hydroxyethyl]iminotris [hydroxymethyl]methane (BIS-TRIS), Glycyl-glycine (GLY-GLY), Triethanolamine (TEA), N-tris [hydroxymethyl]methylglycine (TRICINE), and Tris [hydroxymethyl]aminomethane (TRIZMA), and derivatives or mixtures thereof.
Still in another embodiment, the molecule, residue or sequence has either one acid group and at least one amino group, or more amino groups than acid groups. The molecule, residue or sequence may also be an amino-acid residue, an amino-acid sequence or a poly(amino acids) having a basic character and a pKa between 6.0 and 8.4.
Examples of amino acid residue can be histidine (HIS), arginine (ARG), lysine (LYS), asparagine (ASP), and glutamine (GLN), or a mixture thereof. The amino acid residue may further be modified with a radical acetyl, t-butyl, benzyl, benzoyl, ethyl, formyl, or methyl.
The molecule, residue or sequence is alternatively a sequence, derivative or polymer of at least one amino acid selected from the group
The molecule, residue or sequence is preferably a sodium, magnesium or iron salt selected from the group consisting of N-[carbamoy[methyl]-2-aminoethane sulfonate (ACES), N,N-bis[2-hydroxyethyl]-2-aminoethane sulfonate (BES), 3-[N,N-bis(2-hydroxy-ethyl)amino]-2-hydroxypropanesulfonate (DIPSO), N-[2-hydroxyethyl]piperazine-N'-3-propane-sulfonate (EPPS), N-[2-hydroxyethyl]piperazine-N'-4-butane-sulfonate (HEPBS), N-[2-hydroxyethyl]piperazine-N'-3-propanesu-fonate (HEPES), N-[2-hydroxyethyl] piperazine-N'-2-hydroxypropanesulfonate (HEPSO), 2-[N-morpholino]ethanesulfonate (MES), 4-[N-morpholino]butanesulfonate (MOBS), 3-[N-morpholino]butanesulfonate (MOPS), 3-[N-morpholino]-2-hydroxypropanesulfonate (MOPSO), Piperazine-N,N'-bis[2-ethanesulfonate] (PIPES), Piperazine-N,N'-bis[2-hydroxypropanesulfonate]
(POPSO), 3-[N-tris(hydroxymethyl)methylamino]-2-hydroxypropanesulfonate (TAPSO), and N-tris [hydroxymethyl]methyl-2-minoethanesulfonate(TES), and derivatives or mixtures thereof.
The molecule, residue or sequence is preferably selected from the group consisting of N,N-bis[hydroxyethyl]glycine (BICINE), bis [2-hydroxyethyl]iminotris [hydroxymethyl]methane (BIS-TRIS), Glycyl-glycine (GLY-GLY), Triethanolamine (TEA), N-tris [hydroxymethyl]methylglycine (TRICINE), and Tris [hydroxymethyl]aminomethane (TRIZMA), and derivatives or mixtures thereof.
Still in another embodiment, the molecule, residue or sequence has either one acid group and at least one amino group, or more amino groups than acid groups. The molecule, residue or sequence may also be an amino-acid residue, an amino-acid sequence or a poly(amino acids) having a basic character and a pKa between 6.0 and 8.4.
Examples of amino acid residue can be histidine (HIS), arginine (ARG), lysine (LYS), asparagine (ASP), and glutamine (GLN), or a mixture thereof. The amino acid residue may further be modified with a radical acetyl, t-butyl, benzyl, benzoyl, ethyl, formyl, or methyl.
The molecule, residue or sequence is alternatively a sequence, derivative or polymer of at least one amino acid selected from the group
-5-consisting of alanine (ALA), histidine (HIS), arginine (ARG), lysine (LYS), aspartic acid (ASP), glutamine (GLN), glycine (GLY), hydroxyproline (HYP), isoleucine (ILE), leucine (LEU), norleucine (NLE), phenylaianine (PHE), proline (PRO), serine (SER), threonine (THR), tyrosine (TYR), and valine (VAL).
Preferably, the composition further comprises at least one other water-soluble polymer, such as collagen, methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxyethyl propylcellulose, hydroxymethyl propyl cellulose, polyethylene oxide, polypropylene oxide, poly(ethylene oxide-co-propylene oxide) copolymers, poly(ethylene oxide-co-propylene oxide-co-ethylene oxide) copolymers, polyvinyl alcohol, or polycaprolactone diols, and derivatives or mixtures thereof.
The composition of the present invention may further comprises a solid particulate or a water-soluble additive, such as a drug or a pharmaceutical agent, microorganisms, plant cells, animal cells or human cells dispersed therein.
The composition of the present invention may be used as a carrier for delivering a pharmaceutical agent in situ.
Still in accordance with the present invention, there is provided a method for preparing a composition as defined above. The method comprises the steps of:
a) dissolving a pH-gelling acid-soluble biopolymer within an aqueous acidic solution of a pH from about 1.0 to about 5.0 to obtain an aqueous biopolymer composition having a concentration of 0.1 to 5% by weight of the biopolymer;
b) dissolving 0.1 to 10% by weight of a water-soluble molecule having a basic character and a pKa between 6.0 and 8.4, or a water-soluble residue or sequence of the molecule having a basic character and pKa between 6.0 and 8.4, within the aqueous biopolymer composition to obtain a clear liquid formulation with a pH ranging between 5.8 and 7.4;
c) heating the liquid formulation at a temperature above 30 C to obtain a solid gel, the gel having a pH from about 5.8 to about 7.4.
The composition of the present invention may be used in cosmetics, pharmacology, medicine and/or surgery, into an implantable device or an implant for repair, reconstruction and/or replacement of
Preferably, the composition further comprises at least one other water-soluble polymer, such as collagen, methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxyethyl propylcellulose, hydroxymethyl propyl cellulose, polyethylene oxide, polypropylene oxide, poly(ethylene oxide-co-propylene oxide) copolymers, poly(ethylene oxide-co-propylene oxide-co-ethylene oxide) copolymers, polyvinyl alcohol, or polycaprolactone diols, and derivatives or mixtures thereof.
The composition of the present invention may further comprises a solid particulate or a water-soluble additive, such as a drug or a pharmaceutical agent, microorganisms, plant cells, animal cells or human cells dispersed therein.
The composition of the present invention may be used as a carrier for delivering a pharmaceutical agent in situ.
Still in accordance with the present invention, there is provided a method for preparing a composition as defined above. The method comprises the steps of:
a) dissolving a pH-gelling acid-soluble biopolymer within an aqueous acidic solution of a pH from about 1.0 to about 5.0 to obtain an aqueous biopolymer composition having a concentration of 0.1 to 5% by weight of the biopolymer;
b) dissolving 0.1 to 10% by weight of a water-soluble molecule having a basic character and a pKa between 6.0 and 8.4, or a water-soluble residue or sequence of the molecule having a basic character and pKa between 6.0 and 8.4, within the aqueous biopolymer composition to obtain a clear liquid formulation with a pH ranging between 5.8 and 7.4;
c) heating the liquid formulation at a temperature above 30 C to obtain a solid gel, the gel having a pH from about 5.8 to about 7.4.
The composition of the present invention may be used in cosmetics, pharmacology, medicine and/or surgery, into an implantable device or an implant for repair, reconstruction and/or replacement of
-6-tissues and/or organs, as an implantable, transdermal or dermatological drug delivery system, as an opthalmological implant or a drug delivery system, or in cells-loaded artificial matrices for engineering and culture of bioengineered hybrid materials and tissue equivalents.
The composition may be loaded with cells selected from the group consisting of chondrocytes (articular cartilage), fibrochondrocytes (meniscus), ligament fibroblasts (ligament), skin fibroblasts (skin), tenocytes (tendons), myofibroblasts (muscle), mesenchymal stem cells and keratinocytes (skin). Such composition may be used in culturing and engineering of artificial articular cartilage and cartilageous tissues and organs, either for surgical or laboratory testing applications.
The composition of the present invention may also be used in processing and engineering of living artificial substitutes for ligaments, tendons, skin, bone muscles and any metabolic organs, either for surgical or laboratory testing applications, in living substitutes for the replacement of articular cartilages, fibrocartilages, cartilageous organs, ligaments, tendons, bone tissues or skin, to induce an ectopic formation of fibrocartilage-like or cartilage-like tissues, as an injectable or implantable gel biomaterial which acts as supports, carriers, reconstructive devices or substitutes for the formation in situ of bone-like, fibrocartilage-like or cartilage-like tissues, and/or in cosmetics, pharmacology, medicine and/or surgery.
For the purpose of the present invention the following terms and expressions are defined below.
The term "gelating temperature" is intended to mean any temperature ranging from about 20 C to about 80 C, preferably between C and 60 C, and more preferably at about the physiological temperature or 37 C.
The term "pH-controlled acid-soluble biopolymer" refers to a 30 biological polymer that is solubilized in an acidic aqueous medium, and precipitates or gels heterogeneously when the pH is increased. For example, chitosan is dissolved in acid/water solution at pH about 4.0, and precipitates or gels heterogeneously when the chitosan solution is neutralized at pHs above 6.2.
The composition may be loaded with cells selected from the group consisting of chondrocytes (articular cartilage), fibrochondrocytes (meniscus), ligament fibroblasts (ligament), skin fibroblasts (skin), tenocytes (tendons), myofibroblasts (muscle), mesenchymal stem cells and keratinocytes (skin). Such composition may be used in culturing and engineering of artificial articular cartilage and cartilageous tissues and organs, either for surgical or laboratory testing applications.
The composition of the present invention may also be used in processing and engineering of living artificial substitutes for ligaments, tendons, skin, bone muscles and any metabolic organs, either for surgical or laboratory testing applications, in living substitutes for the replacement of articular cartilages, fibrocartilages, cartilageous organs, ligaments, tendons, bone tissues or skin, to induce an ectopic formation of fibrocartilage-like or cartilage-like tissues, as an injectable or implantable gel biomaterial which acts as supports, carriers, reconstructive devices or substitutes for the formation in situ of bone-like, fibrocartilage-like or cartilage-like tissues, and/or in cosmetics, pharmacology, medicine and/or surgery.
For the purpose of the present invention the following terms and expressions are defined below.
The term "gelating temperature" is intended to mean any temperature ranging from about 20 C to about 80 C, preferably between C and 60 C, and more preferably at about the physiological temperature or 37 C.
The term "pH-controlled acid-soluble biopolymer" refers to a 30 biological polymer that is solubilized in an acidic aqueous medium, and precipitates or gels heterogeneously when the pH is increased. For example, chitosan is dissolved in acid/water solution at pH about 4.0, and precipitates or gels heterogeneously when the chitosan solution is neutralized at pHs above 6.2.
-7-The expression "three-dimensional" refers herein to the fact that the polymeric solution is simultaneously gelated and shaped by the mold wherein the solution was initially poured. Gels can be produced in glass or plastic bechers, dishes, tubes or between two plates so as to obtain any expected shapes.
The expression "in situ gelation" refers herein to the formation of gels by injecting the liquid solution within specific sites of mammalian or human environments, e.g. any tissues (muscles, bone, ligaments, cartilages) and organs. Gelation in situ allows complete and precise filling of tissue defects or body cavities. The gelation of biopolymer mixture is induced by the physiological temperature.
The expression "endothermal gelation" refers herein to the thermal mechanism of the solution, which enables the solution to gelate upon standing at the desired temperature. Induction of sol to gel transitions of systems requires energy via, for example, the temperature.
The expression "residue" refers herein to a series of biochemical molecules having a common specific chemical function. Example: the amino acid residues.
The expression "sequence" refers herein to the association of two or several molecules or residues. Example: a sequence of amino acid residues (LYS-ASP-PRO-GLY-LYS).
The expression "basic character" refers herein to the ability of a chemical molecule in aqueous solution to capture protons (H+), thus leading to an increase in pH.
The expression "cells or cellular matters" refers herein to living biologicals, such as isolated cells, cellular dispersion, cell aggregates, cell spheroids or cells adhered to solid microspheres particles, that are encapsulated within the gels.
It is assumed herein that any pH-gelling acid-soluble biopolymers or polymers would behave similarly. As a consequence, the term "biopolymer" in the present invention may be replaced by the term "polymer", "polypeptide", "poly(amino acids)".
The present invention include method of forming different gelated materials, those materials being either molded (customized
The expression "in situ gelation" refers herein to the formation of gels by injecting the liquid solution within specific sites of mammalian or human environments, e.g. any tissues (muscles, bone, ligaments, cartilages) and organs. Gelation in situ allows complete and precise filling of tissue defects or body cavities. The gelation of biopolymer mixture is induced by the physiological temperature.
The expression "endothermal gelation" refers herein to the thermal mechanism of the solution, which enables the solution to gelate upon standing at the desired temperature. Induction of sol to gel transitions of systems requires energy via, for example, the temperature.
The expression "residue" refers herein to a series of biochemical molecules having a common specific chemical function. Example: the amino acid residues.
The expression "sequence" refers herein to the association of two or several molecules or residues. Example: a sequence of amino acid residues (LYS-ASP-PRO-GLY-LYS).
The expression "basic character" refers herein to the ability of a chemical molecule in aqueous solution to capture protons (H+), thus leading to an increase in pH.
The expression "cells or cellular matters" refers herein to living biologicals, such as isolated cells, cellular dispersion, cell aggregates, cell spheroids or cells adhered to solid microspheres particles, that are encapsulated within the gels.
It is assumed herein that any pH-gelling acid-soluble biopolymers or polymers would behave similarly. As a consequence, the term "biopolymer" in the present invention may be replaced by the term "polymer", "polypeptide", "poly(amino acids)".
The present invention include method of forming different gelated materials, those materials being either molded (customized
-8-shapes, tubes, membranes, films...) or formed in situ within biological environments (filling of tissue defects).
In a preferred embodiment, the self-gelling biopolymer aqueous solution has a pH above that for normal precipitation, and turn into solid gel upon thermal stimulation. This biopolymer gel can be used as a carrier for drugs or as a non-living therapeutics delivery systems, as substituting materials for tissues and organs and as encapsulants for living cells or microorganisms. Gel matrices are rapidly formed at temperatures between 30 to 60 C. Such aqueous systems are used as injectable filling materials, injected and gelated in situ for filling and repairing tissue defects.
In a second preferred embodiment, pH-dependant gelling acid water-soluble biopolymers and derivatives having a sufficient hydrophilicity are selected for preparing temperature-stimulated gels.
Biopolymeric gels can be applied to surgical reconstructive and regeneration uses and drug delivery purposes. They provide thermally reversible or irreversible bioerodible polymeric gels with biologically well-known and compatible components for a broad range of medical/biotechnological applications.
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 illustrates a plot of the Elastic Modulus G' (Pa) vs.
Temperature (Celsius) illustrating the thermal gelling/ungelling of chitosan (2% w/v, deacetylation 85%) solution with MOPS (2.0% w/v) upon cooling/heating;
Fig. 2 illustrates a plot of the elastic modulus G' (Pa) vs.
Temperature (Celsius) illustrating the thermal gelling/ungelling of chitosan (2% w/v, deacetylation 85%) solution with MOPSO (3.0% w/v) upon cooling/heating;
Fig. 3 illustrates a plot of the Elastic Modulus G' (Pa) vs.
Temperature (Celsius) illustrating the thermal gelling/ungelling of chitosan (2% w/v, deacetylation 85%) solution with BIS-TRIS (3.0% w/v) upon cooling/heating;
Fig. 4 illustrates a plot of the Elastic Modulus G' (Pa) vs.
Temperature (Celsius) illustrating the thermal gelling/ungelling of chitosan (2% w/v, deacetylation 85%) solution with MES (8.0% w/v) upon
In a preferred embodiment, the self-gelling biopolymer aqueous solution has a pH above that for normal precipitation, and turn into solid gel upon thermal stimulation. This biopolymer gel can be used as a carrier for drugs or as a non-living therapeutics delivery systems, as substituting materials for tissues and organs and as encapsulants for living cells or microorganisms. Gel matrices are rapidly formed at temperatures between 30 to 60 C. Such aqueous systems are used as injectable filling materials, injected and gelated in situ for filling and repairing tissue defects.
In a second preferred embodiment, pH-dependant gelling acid water-soluble biopolymers and derivatives having a sufficient hydrophilicity are selected for preparing temperature-stimulated gels.
Biopolymeric gels can be applied to surgical reconstructive and regeneration uses and drug delivery purposes. They provide thermally reversible or irreversible bioerodible polymeric gels with biologically well-known and compatible components for a broad range of medical/biotechnological applications.
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 illustrates a plot of the Elastic Modulus G' (Pa) vs.
Temperature (Celsius) illustrating the thermal gelling/ungelling of chitosan (2% w/v, deacetylation 85%) solution with MOPS (2.0% w/v) upon cooling/heating;
Fig. 2 illustrates a plot of the elastic modulus G' (Pa) vs.
Temperature (Celsius) illustrating the thermal gelling/ungelling of chitosan (2% w/v, deacetylation 85%) solution with MOPSO (3.0% w/v) upon cooling/heating;
Fig. 3 illustrates a plot of the Elastic Modulus G' (Pa) vs.
Temperature (Celsius) illustrating the thermal gelling/ungelling of chitosan (2% w/v, deacetylation 85%) solution with BIS-TRIS (3.0% w/v) upon cooling/heating;
Fig. 4 illustrates a plot of the Elastic Modulus G' (Pa) vs.
Temperature (Celsius) illustrating the thermal gelling/ungelling of chitosan (2% w/v, deacetylation 85%) solution with MES (8.0% w/v) upon
-9-cooling/heating;
Fig. 5 illustrates a plot of the Elastic Modulus (Pa) vs.
Temperature (Celsius) illustrating the thermal gelling/ungelling of chitosan (2% w/v, deacetylation 85%) solution with BES (2.0% w/v) upon cooling/heating;
Fig. 6 illustrates a plot of the Turbidimetry (NTU) vs. Time illustrating the thermal gelling of chitosan (2% w/v, deacetylation 85%) solution with GP (8.0% w/v, pH=7.2) and without GP (pH=5.4) at 37 C;
Fig. 7 illustrates a plot of the Turbidimetry (NTU) vs. Time illustrating the thermal gelling of chitosan (2% w/v, deacetylation 85%) solution with BES (2.0% w/v) and without BES (pH=5.4) at 37 C; and Fig. 8 illustrates a plot of the Turbidimetry (NTU) vs. Time illustrating the thermal gelling of chitosan (2% w/v, deacetylation 85%) solution with BIS-TRIS, at different BIS-TRIS content, from 2.0 to 4.0%
w/v, at 37 C.
DETAILED DESCRIPTION OF THE INVENTION
In accordance with the present invention there is proposed a new gelation mechanism that combines hydrogen bonding, electrostatic interactions and hydrophilic/hydrophobic interactions. It can only be achieved through complex interactions between biological macromolecules or synthetic polymers, water molecules and specific biochemical molecules having special actions.
In accordance with the present invention, the concerned biopolymer should be insoluble in water under neutral conditions pH = 7.
A method is disclosed for preparing a composition which comprises the steps a) of dissolving a pH-gelling acid-soluble biopolymer within an aqueous acidic solution of a pH from about 1.0 to about 5.0 to obtain an aqueous biopolymer composition having a concentration of 0.1 to 5% by weight of said biopolymer, and b) dissolving 0.1 to 10% by weight of a water-soluble molecule having a moderate basic character, or any water-soluble sequence of said molecule, within said aqueous biopolymer composition to obtain a clear liquid formulation with a pH ranging between 6.5 and 7.4. The final step is the heating of liquid formulation at a temperature above 30 C to obtain a solid gel, wherein said gel has a
Fig. 5 illustrates a plot of the Elastic Modulus (Pa) vs.
Temperature (Celsius) illustrating the thermal gelling/ungelling of chitosan (2% w/v, deacetylation 85%) solution with BES (2.0% w/v) upon cooling/heating;
Fig. 6 illustrates a plot of the Turbidimetry (NTU) vs. Time illustrating the thermal gelling of chitosan (2% w/v, deacetylation 85%) solution with GP (8.0% w/v, pH=7.2) and without GP (pH=5.4) at 37 C;
Fig. 7 illustrates a plot of the Turbidimetry (NTU) vs. Time illustrating the thermal gelling of chitosan (2% w/v, deacetylation 85%) solution with BES (2.0% w/v) and without BES (pH=5.4) at 37 C; and Fig. 8 illustrates a plot of the Turbidimetry (NTU) vs. Time illustrating the thermal gelling of chitosan (2% w/v, deacetylation 85%) solution with BIS-TRIS, at different BIS-TRIS content, from 2.0 to 4.0%
w/v, at 37 C.
DETAILED DESCRIPTION OF THE INVENTION
In accordance with the present invention there is proposed a new gelation mechanism that combines hydrogen bonding, electrostatic interactions and hydrophilic/hydrophobic interactions. It can only be achieved through complex interactions between biological macromolecules or synthetic polymers, water molecules and specific biochemical molecules having special actions.
In accordance with the present invention, the concerned biopolymer should be insoluble in water under neutral conditions pH = 7.
A method is disclosed for preparing a composition which comprises the steps a) of dissolving a pH-gelling acid-soluble biopolymer within an aqueous acidic solution of a pH from about 1.0 to about 5.0 to obtain an aqueous biopolymer composition having a concentration of 0.1 to 5% by weight of said biopolymer, and b) dissolving 0.1 to 10% by weight of a water-soluble molecule having a moderate basic character, or any water-soluble sequence of said molecule, within said aqueous biopolymer composition to obtain a clear liquid formulation with a pH ranging between 6.5 and 7.4. The final step is the heating of liquid formulation at a temperature above 30 C to obtain a solid gel, wherein said gel has a
-10-concentration of 0.1 to 5.0% by weight of said biopolymer, and a concentration of 0.1 to 10% by weight of said molecule, and has a pH from about 6.4 to about 7.4:
The aqueous acidic solution is prepared from organic or inorganic acids that are selected from the group consisting of acetic acid, ascorbic acid, glutamic acid, lactic acid, lactobionic acid, salicylic acid, phosphoric acid, hydrochloric acid, propionic acid, formic acid, and a mixture thereof. Solubilization of pH-controlled acid-soluble biopolymers in aqueous solution requires acidic aqueous solutions having a pH ranging from 1.0 to 5Ø
The selected biopolymer is a pH-gelling acid-soluble polysaccharide, polypeptidic or poly(amino acids), or synthetic polymer.
The preferred polysaccharide is selected from a group comprising chitosan, modified chitosan or chitosan derivative, said chitosan biopolymer being cationic and bearing amino groups.
The acid-soluble polypeptide is selected from collageneous proteins, preferentially collagen.
A second polymer, selected from a groups comprising collagen, methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxyethyl propylcellulose, hydroxymethyl propyl cellulose, polyethylene oxide, polypropylene oxide, poly(ethylene oxide-co-propylene oxide) copolymers, poly(ethylene oxide-co-propylene oxide-co-ethylene oxide) copolymers, polyvinyl alcohol, polycaprolactone diols, and derivatives, and any mixture thereof, can be incorporated within the biopolymeric solution.
The admixed molecule is required to play a double role: 1) to increase the pH within the biopolymeric solution up the physiological conditions, and 2) to prevent the immediate gelation or aggregation. The required molecule, preferentially selected from organic salts and amino-acids, should have a moderate basic character and a pKa between 6.0 and 7.6. Typically, the selected molecule should have a great sensitivity in terms of hydrophilicity/hydrophobicity (hydrophobic hydration and dehydration) and thermal sensitivity. Such effects are based upon a competition for hydration between apolar and polar groups of said molecule, which enables the design of molecular machines by free energy conversion.
The aqueous acidic solution is prepared from organic or inorganic acids that are selected from the group consisting of acetic acid, ascorbic acid, glutamic acid, lactic acid, lactobionic acid, salicylic acid, phosphoric acid, hydrochloric acid, propionic acid, formic acid, and a mixture thereof. Solubilization of pH-controlled acid-soluble biopolymers in aqueous solution requires acidic aqueous solutions having a pH ranging from 1.0 to 5Ø
The selected biopolymer is a pH-gelling acid-soluble polysaccharide, polypeptidic or poly(amino acids), or synthetic polymer.
The preferred polysaccharide is selected from a group comprising chitosan, modified chitosan or chitosan derivative, said chitosan biopolymer being cationic and bearing amino groups.
The acid-soluble polypeptide is selected from collageneous proteins, preferentially collagen.
A second polymer, selected from a groups comprising collagen, methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxyethyl propylcellulose, hydroxymethyl propyl cellulose, polyethylene oxide, polypropylene oxide, poly(ethylene oxide-co-propylene oxide) copolymers, poly(ethylene oxide-co-propylene oxide-co-ethylene oxide) copolymers, polyvinyl alcohol, polycaprolactone diols, and derivatives, and any mixture thereof, can be incorporated within the biopolymeric solution.
The admixed molecule is required to play a double role: 1) to increase the pH within the biopolymeric solution up the physiological conditions, and 2) to prevent the immediate gelation or aggregation. The required molecule, preferentially selected from organic salts and amino-acids, should have a moderate basic character and a pKa between 6.0 and 7.6. Typically, the selected molecule should have a great sensitivity in terms of hydrophilicity/hydrophobicity (hydrophobic hydration and dehydration) and thermal sensitivity. Such effects are based upon a competition for hydration between apolar and polar groups of said molecule, which enables the design of molecular machines by free energy conversion.
-11-Other preferred molecules, residues or sequences are organic salts selected from mono-phosphate salts, mono-sulfonate salts, mono-sulfate salts or mono-carboxylate salts; said organic salts being water-soluble and having a basic character and a pKa between 6.0 and 7.6.
The organic salt is preferably a salt of polyol or sugar selected from mono-phosphate dibasic salts, mono-sulfonate salts, mono-sulfate salts or mono-carboxylate salts of polyol, said polyol being selected from the group consisting of glycerol, comprising glycerol-2-phosphate, sn-glycerol 3-phosphate and L-glycerol-3-phosphate salts, and any mixture thereof. Salt of polyol or sugar are known to greatly modify the behavior of biopolymeric acidic aqueous solutions.
The salt of polyol is preferably selected from mono-phosphate dibasic salts, mono-sulfonate salts, mono-sulfate salts or mono-carboxylate salts of polyol, said polyol being selected from a group of polyols comprising histidinol, acetol, diethylstil-bestrol, indole-glycerol, sorbitol, ribitol, xylitol, arabinitol, erythritol, inositol, mannitol, glucitol, palmitoyl-glycerol, linoleoyl-glycerol, oleoyl-glycerol, arachidonoyl-glycerol, and any mixture thereof.
The salt of sugar is preferably selected from mono-phosphate dibasic salts, mono-sulfonate salts, mono-sulfate salts or mono-carboxylate salts of sugar, said sugar being selected from a group of sugars consisting of fructose, galactose, ribose, glucose, xylose, rhamnulose, sorbose, erythrulose, deoxy-ribose, ketose, mannose, arabinose, fuculose, fructopyranose, ketoglucose, sedoheptulose, trehalose, tagatose, sucrose, allose, threose, xylulose, hexose, methylthio-ribose, methylthio-deoxy-ribulose, and any mixture thereof.
Polyols are frequently added to compositions for improving gel properties. Sorbitol and mannitol are currently used as tonicity enhancing agents. Glycerol and polyethylene glycol are proposed as plasticizers.
Polyols (-ol: glycerol, sorbitol...) and sugars (-ose: fructose, glucose, galactose...) were used as thermal stabilizing agents for proteins in solutions Depending on the selected molecules, they were found to make or break structuring of water, create hydrogen bonding, electrostatic or hydrophobic interacting, and present endothermic transitions Polyols and
The organic salt is preferably a salt of polyol or sugar selected from mono-phosphate dibasic salts, mono-sulfonate salts, mono-sulfate salts or mono-carboxylate salts of polyol, said polyol being selected from the group consisting of glycerol, comprising glycerol-2-phosphate, sn-glycerol 3-phosphate and L-glycerol-3-phosphate salts, and any mixture thereof. Salt of polyol or sugar are known to greatly modify the behavior of biopolymeric acidic aqueous solutions.
The salt of polyol is preferably selected from mono-phosphate dibasic salts, mono-sulfonate salts, mono-sulfate salts or mono-carboxylate salts of polyol, said polyol being selected from a group of polyols comprising histidinol, acetol, diethylstil-bestrol, indole-glycerol, sorbitol, ribitol, xylitol, arabinitol, erythritol, inositol, mannitol, glucitol, palmitoyl-glycerol, linoleoyl-glycerol, oleoyl-glycerol, arachidonoyl-glycerol, and any mixture thereof.
The salt of sugar is preferably selected from mono-phosphate dibasic salts, mono-sulfonate salts, mono-sulfate salts or mono-carboxylate salts of sugar, said sugar being selected from a group of sugars consisting of fructose, galactose, ribose, glucose, xylose, rhamnulose, sorbose, erythrulose, deoxy-ribose, ketose, mannose, arabinose, fuculose, fructopyranose, ketoglucose, sedoheptulose, trehalose, tagatose, sucrose, allose, threose, xylulose, hexose, methylthio-ribose, methylthio-deoxy-ribulose, and any mixture thereof.
Polyols are frequently added to compositions for improving gel properties. Sorbitol and mannitol are currently used as tonicity enhancing agents. Glycerol and polyethylene glycol are proposed as plasticizers.
Polyols (-ol: glycerol, sorbitol...) and sugars (-ose: fructose, glucose, galactose...) were used as thermal stabilizing agents for proteins in solutions Depending on the selected molecules, they were found to make or break structuring of water, create hydrogen bonding, electrostatic or hydrophobic interacting, and present endothermic transitions Polyols and
-12-sugars stabilize proteins to heat denaturation through their structuring effect on water and the strengthen of hydrophobic interactions.
The molecule, residue or sequence is preferably a salt selected in a group comprising N-[carbamoylmethyl]-2-aminoethane sulfonate (ACES), N,N-bis[2-hydroxyethyl]-2-aminoethane sulfonate (BES), 3-[N,N-bis(2-hydroxy-ethyl)amino]-2-hydroxypropanesulfonate (DI PSO), N-[2-hydroxyethyl]piperazine-N'-3-propanesulfonate (HEPES), 2-[N-morpholino]ethanesulfonate (MES), 4-[N-morpholino] butanesulfonate (MOBS), 3-[N-morpholino]butanesulfonate (MOPS), 3-[N-morpholino]-2-hydroxypropanesulfonate (MOPSO), 3-[N-tris(hydroxymethyl)methylamino]-2-hydroxypropanesulfonate (TAPSO), N-tris [hydroxymethyl] methyl-2-minoethanesulfonate(TES), bis [2-hydroxy-ethyl]iminotris [hydroxymethyl]methane (BIS-TRIS), 3-mopholino 1-1-propane diol, and derivatives, and any mixture thereof.
The molecule, residue or sequence is preferably selected from amino-acid residues, amino-acid sequences or poly(amino acids) having a basic character and a pKa between 6.0 and 7.6, preferentially histidine (His).
The molecule, residue or sequence is preferably a sequence, derivative or oligomer of amino acids including alanine, (ALA), histidine (HIS), arginine (ARG), lysine (LYS), aspartic acid (ASP), glutamine (GLN), glycine (GLY), hydroxyproline (HYP), isoleucine (ILE), leucine (LEU), norleucine (NLE), phenylalanine (PHE), proline (PRO), serine (SER), threonine (THR), tyrosine (TYR), and valine (VAL).
A pharmaceutical or bioactive agent can be added to the liquid biopolymer containing solution of step a) or b). It can be highly soluble, sparingly soluble or non-soluble in the aqueous formulation. Solid particulate additives such as non-polymeric microspheres or nanospheres, mineral or ceramic granules or powders, can be added to the biopolymer solution of step a) or b).
The mixture can be dispensed for gelation into a desired receiver, either in a mold or within a tissue, organ or body cavity. It can be kept in a stable ungelled liquid form at a temperature ranging from about 0 C to about 20 C. The solidifying temperature is ranging from about 37 C
to about 60 C, and preferably about 37 C.
The molecule, residue or sequence is preferably a salt selected in a group comprising N-[carbamoylmethyl]-2-aminoethane sulfonate (ACES), N,N-bis[2-hydroxyethyl]-2-aminoethane sulfonate (BES), 3-[N,N-bis(2-hydroxy-ethyl)amino]-2-hydroxypropanesulfonate (DI PSO), N-[2-hydroxyethyl]piperazine-N'-3-propanesulfonate (HEPES), 2-[N-morpholino]ethanesulfonate (MES), 4-[N-morpholino] butanesulfonate (MOBS), 3-[N-morpholino]butanesulfonate (MOPS), 3-[N-morpholino]-2-hydroxypropanesulfonate (MOPSO), 3-[N-tris(hydroxymethyl)methylamino]-2-hydroxypropanesulfonate (TAPSO), N-tris [hydroxymethyl] methyl-2-minoethanesulfonate(TES), bis [2-hydroxy-ethyl]iminotris [hydroxymethyl]methane (BIS-TRIS), 3-mopholino 1-1-propane diol, and derivatives, and any mixture thereof.
The molecule, residue or sequence is preferably selected from amino-acid residues, amino-acid sequences or poly(amino acids) having a basic character and a pKa between 6.0 and 7.6, preferentially histidine (His).
The molecule, residue or sequence is preferably a sequence, derivative or oligomer of amino acids including alanine, (ALA), histidine (HIS), arginine (ARG), lysine (LYS), aspartic acid (ASP), glutamine (GLN), glycine (GLY), hydroxyproline (HYP), isoleucine (ILE), leucine (LEU), norleucine (NLE), phenylalanine (PHE), proline (PRO), serine (SER), threonine (THR), tyrosine (TYR), and valine (VAL).
A pharmaceutical or bioactive agent can be added to the liquid biopolymer containing solution of step a) or b). It can be highly soluble, sparingly soluble or non-soluble in the aqueous formulation. Solid particulate additives such as non-polymeric microspheres or nanospheres, mineral or ceramic granules or powders, can be added to the biopolymer solution of step a) or b).
The mixture can be dispensed for gelation into a desired receiver, either in a mold or within a tissue, organ or body cavity. It can be kept in a stable ungelled liquid form at a temperature ranging from about 0 C to about 20 C. The solidifying temperature is ranging from about 37 C
to about 60 C, and preferably about 37 C.
-13-Practically, the mixture is introduced within an animal or human body by injection or endoscopic administration, and gelled in situ at a temperature of about 37 C.
Table 1 below provides composition of some preferred examples for buffering/gelling agents with a 2% w/v chitosan solution (deacetylation 85%).
Agent pKa Concentration pH Intrinsic Gelling mM Temp erature C
BES 7.1 85.03 7.1 38.5 MOPS 7.2 86.5 7.2 32 MOPSO 6.9 121.35 7.2 32.2 BIS-TRIS 6.5 191.20 7.15 25.5 MES 6.1 361.0 7.2 35.5 Formation of biopolymeric gels A selected biopolymer in powder form is dissolved in an aqueous acidic solution until the occurrence of a clear solution is obtained. The proportion of biopolymer varies from 0.5 to 10.0% w/v, preferentially from 1.0 to 3.0% w/v. The pH of the aqueous biopolymer solution ranges from 4.0 to 5.5. Aqueous biopolymer solutions can be sterilized either by autoclaving or filtration with in-line sterile filters (0.22 micrometer).
Freshly-prepared aqueous biopolymer solutions are stored preferably at low positive temperature (4 C). The added molecule with a moderate basic character is dissolved in water, then admixed to the aqueous biopolymer solution at a temperatures ranging from 4 to 15 C, preferably 10 C. When a clear homogeneous aqueous solution with a pH ranging from 5.8 to 7.0 is attained, the said solution is poured into the desired receiver, and hold to appropriate temperature to gel.
The nature of the acid that is used for the acidic biopolymer solutions does not influence fundamentally the sol to gel transition of the system. The final pH within the solution is dependent upon the pH of the water/acid solution as well as the biopolymer and molecule concentrations.
As the biopolymer and molecule are two basic components, they tend to
Table 1 below provides composition of some preferred examples for buffering/gelling agents with a 2% w/v chitosan solution (deacetylation 85%).
Agent pKa Concentration pH Intrinsic Gelling mM Temp erature C
BES 7.1 85.03 7.1 38.5 MOPS 7.2 86.5 7.2 32 MOPSO 6.9 121.35 7.2 32.2 BIS-TRIS 6.5 191.20 7.15 25.5 MES 6.1 361.0 7.2 35.5 Formation of biopolymeric gels A selected biopolymer in powder form is dissolved in an aqueous acidic solution until the occurrence of a clear solution is obtained. The proportion of biopolymer varies from 0.5 to 10.0% w/v, preferentially from 1.0 to 3.0% w/v. The pH of the aqueous biopolymer solution ranges from 4.0 to 5.5. Aqueous biopolymer solutions can be sterilized either by autoclaving or filtration with in-line sterile filters (0.22 micrometer).
Freshly-prepared aqueous biopolymer solutions are stored preferably at low positive temperature (4 C). The added molecule with a moderate basic character is dissolved in water, then admixed to the aqueous biopolymer solution at a temperatures ranging from 4 to 15 C, preferably 10 C. When a clear homogeneous aqueous solution with a pH ranging from 5.8 to 7.0 is attained, the said solution is poured into the desired receiver, and hold to appropriate temperature to gel.
The nature of the acid that is used for the acidic biopolymer solutions does not influence fundamentally the sol to gel transition of the system. The final pH within the solution is dependent upon the pH of the water/acid solution as well as the biopolymer and molecule concentrations.
As the biopolymer and molecule are two basic components, they tend to
-14-increase the pH of the acidic solution wherein they are dissolved.
Concentrations in this biopolymer and molecule can be balanced to reach the appropriate pH of the solution, while taking into consideration the solubility limit of both components, and particularly the one of biopolymer.
In situ formation of gels The selected molecule tested to be incorporated in the polymeric solution was histidine, but similar results were obtained with other amino acids or synthetic molecules having similar functions and basic character.
In situ gelation of the biopolymer solution can be conducted by dispensing the solution from a hypodermic syringe. If needed, the solution may be pre-gelated (initiate the thermal gelation) by keeping the syringe and biopolymer solution at desired temperature, ideally 37 C, until the first signs of gelation appear. The ready-to-gel biopolymer mixture is then administrated so as to fill tissue defects or cavities and complete in situ the gelation process (at 37 C). A needle having a gauge of 20 and below is ideal material for injection of such gel solution. Body cavities and tissue defects act as recipients for the solution, but the liquid materials remain in an open aqueous environment. The conformability and diffusability of the biopolymer solutions is dependent upon the solution and material properties. Increased viscosity results in formation in situ of more compact and less conformable gels.
Therapeutic use and other uses of biopolymeric Gels Such a biopolymeric gel as previously described is an ideal material for drug delivery system. Such a in situ gel-like forming vehicle, wherein a solid particulate or water-soluble additive is incorporated prior to the gelation, can be administrated topically, directly to the body site to be treated or diagnosed. Anti-bacterial, anti-fungal, steroidal or non-steroidal anti-inflammatory, anti-cancer, anti-fibrosis, anti-viral, anti-glucoma, miotic and anti-cholinergies, anti-psychotic, anti-histaminic and decongestant, anesthesic and anti-parasitic agents may be incorporated within the composition and gel. In a similar fashion, non-living pharmaceutical agents may be incorporated within the composition or gel for restorative, re-constructive or regenerative purposes.
Concentrations in this biopolymer and molecule can be balanced to reach the appropriate pH of the solution, while taking into consideration the solubility limit of both components, and particularly the one of biopolymer.
In situ formation of gels The selected molecule tested to be incorporated in the polymeric solution was histidine, but similar results were obtained with other amino acids or synthetic molecules having similar functions and basic character.
In situ gelation of the biopolymer solution can be conducted by dispensing the solution from a hypodermic syringe. If needed, the solution may be pre-gelated (initiate the thermal gelation) by keeping the syringe and biopolymer solution at desired temperature, ideally 37 C, until the first signs of gelation appear. The ready-to-gel biopolymer mixture is then administrated so as to fill tissue defects or cavities and complete in situ the gelation process (at 37 C). A needle having a gauge of 20 and below is ideal material for injection of such gel solution. Body cavities and tissue defects act as recipients for the solution, but the liquid materials remain in an open aqueous environment. The conformability and diffusability of the biopolymer solutions is dependent upon the solution and material properties. Increased viscosity results in formation in situ of more compact and less conformable gels.
Therapeutic use and other uses of biopolymeric Gels Such a biopolymeric gel as previously described is an ideal material for drug delivery system. Such a in situ gel-like forming vehicle, wherein a solid particulate or water-soluble additive is incorporated prior to the gelation, can be administrated topically, directly to the body site to be treated or diagnosed. Anti-bacterial, anti-fungal, steroidal or non-steroidal anti-inflammatory, anti-cancer, anti-fibrosis, anti-viral, anti-glucoma, miotic and anti-cholinergies, anti-psychotic, anti-histaminic and decongestant, anesthesic and anti-parasitic agents may be incorporated within the composition and gel. In a similar fashion, non-living pharmaceutical agents may be incorporated within the composition or gel for restorative, re-constructive or regenerative purposes.
-15-Living microorganisms, plant cells, animal cells or human cells may be entrapped identically within the biopolymer gel by introduction prior to the gelation. The cells or micro-organisms loaded gels may be applied to biotechnological purposes in medicine or in other industrial areas.
Biopolymer in situ forming gels can be formed sub-cutaneously, intramuscularly, intra-peritoneally or within biological connective tissues, bone defects, fractures, articular cavities, body conduits or cavities, eye cul-de-sac, solid tumor vasculatures, etc...
The present invention will be more readily understood by referring to the following examples, which are given to illustrate the invention rather than to limit its scope.
EXAMPLE I
This example shows typical experiments of acidic biopolymer solutions neutralized with an organo-phosphate, preferentially glycerophosphate (GP), and transformed to gel upon standing at 37 C.
Experiment 1: gelation of chitosan/GP
In typical experiment, 200 mg of chitosan 85% deacetylated was dissolved in 8.5 mL of aqueous HCI solution (0.1 M). The chitosan solution, so obtained had a pH of about 5.0, was cooled down to around 4 C. Then 800 mg of P-glycerophosphate disodium salt pentahydrate dissolved in 1.5 mL of water were added slowly to the chitosan solution, while maintaining the cold temperature. The pH of the resulting homogeneous and clear liquid mixture become 7.1. This mixture was disposed in a glass scintillation vial in the incubator at 37 C for 2 hours, enough time to achieve bulk gelation process.
Similar results were obtained when the R-glycerophosphate disodium salt was replaced by the a- glycerophosphate disodium salt.
Experiment 2: gelation of collagen/GP
Collagen was isolated from knee joint cartilage of calf, and was made mainly of type II collagen. An aqueous solution of coliagen (2% w/v) was prepared by dissolving 0.2 g of collagen in 8.5 ml of an acetic acid solution with a pH about 3.6. Once a clear solution was obtained, it was
Biopolymer in situ forming gels can be formed sub-cutaneously, intramuscularly, intra-peritoneally or within biological connective tissues, bone defects, fractures, articular cavities, body conduits or cavities, eye cul-de-sac, solid tumor vasculatures, etc...
The present invention will be more readily understood by referring to the following examples, which are given to illustrate the invention rather than to limit its scope.
EXAMPLE I
This example shows typical experiments of acidic biopolymer solutions neutralized with an organo-phosphate, preferentially glycerophosphate (GP), and transformed to gel upon standing at 37 C.
Experiment 1: gelation of chitosan/GP
In typical experiment, 200 mg of chitosan 85% deacetylated was dissolved in 8.5 mL of aqueous HCI solution (0.1 M). The chitosan solution, so obtained had a pH of about 5.0, was cooled down to around 4 C. Then 800 mg of P-glycerophosphate disodium salt pentahydrate dissolved in 1.5 mL of water were added slowly to the chitosan solution, while maintaining the cold temperature. The pH of the resulting homogeneous and clear liquid mixture become 7.1. This mixture was disposed in a glass scintillation vial in the incubator at 37 C for 2 hours, enough time to achieve bulk gelation process.
Similar results were obtained when the R-glycerophosphate disodium salt was replaced by the a- glycerophosphate disodium salt.
Experiment 2: gelation of collagen/GP
Collagen was isolated from knee joint cartilage of calf, and was made mainly of type II collagen. An aqueous solution of coliagen (2% w/v) was prepared by dissolving 0.2 g of collagen in 8.5 ml of an acetic acid solution with a pH about 3.6. Once a clear solution was obtained, it was
-16-cooled down to about 4 C, and then a cold solution of 800 mg of [i-glycerophosphate disodium salt pentahydrate in 1.5 mL of water was added under continuous stirring. When the resulting neutral solution (pH =
7.2) appeared quite homogeneous and clear, it was poured in a Petri dish and placed at 37 C. A homogeneous uniform gel formed within 1 hour.
Experiment 3: gelation of chitosan-Collacgen/GP
Collagen (100 mg) of the same origin (Example 1, Experiment 2) was first dissolved in 10 mi of an acetic acid solution (0.1 M). Then 100 mg of Chitosan was added to the resulting solution and stirred until all chitosan was completely dissolved. After the whole system was cooled down to around 4 C, and 800 mg of [i-glycerophosphate disodium salt, dissolved in 1.5 ml of water, was added under continuous stirring. Once the resulting neutral solution (pH = 7.2) was perfectly homogeneous and clear, it was poured in a Petri dish and placed at 37 C. The gel formed within 1 hour.
Example 2 This example shows the typical experiments of acidic biopolymer solutions neutralized with organo-sulfonate, preferentially N,N-bis[2-hydroxyethyl]-2-aminoethane sulfonate (BES), and transformed to gel upon standing at 37 C.
Experiment 1: gelation of chitosan/BES
In this experiment, 200 mg of chitosan 85% deacetylated was dissolved in 8.5 mL of aqueous HCI solution (0.1 M). The chitosan solution, so obtained had a pH of about 5.0, was cooled down to around 4 C. Then 200 mg of BES in form of sodium salt was dissolved in 1.5 mL of cold water and added slowly to the cold chitosan solution under vigorous stirring. The pH of the resulting homogeneous and clear solution increases to about 7.17. This solution was disposed in a glass scintillation vial in the incubator at 37 C. Bulk gelation occurs in 10 minutes.
Experiment 2: gelation of coliagen/BES
Collagen was of the same origin (Example 1, Experiment 2). An
7.2) appeared quite homogeneous and clear, it was poured in a Petri dish and placed at 37 C. A homogeneous uniform gel formed within 1 hour.
Experiment 3: gelation of chitosan-Collacgen/GP
Collagen (100 mg) of the same origin (Example 1, Experiment 2) was first dissolved in 10 mi of an acetic acid solution (0.1 M). Then 100 mg of Chitosan was added to the resulting solution and stirred until all chitosan was completely dissolved. After the whole system was cooled down to around 4 C, and 800 mg of [i-glycerophosphate disodium salt, dissolved in 1.5 ml of water, was added under continuous stirring. Once the resulting neutral solution (pH = 7.2) was perfectly homogeneous and clear, it was poured in a Petri dish and placed at 37 C. The gel formed within 1 hour.
Example 2 This example shows the typical experiments of acidic biopolymer solutions neutralized with organo-sulfonate, preferentially N,N-bis[2-hydroxyethyl]-2-aminoethane sulfonate (BES), and transformed to gel upon standing at 37 C.
Experiment 1: gelation of chitosan/BES
In this experiment, 200 mg of chitosan 85% deacetylated was dissolved in 8.5 mL of aqueous HCI solution (0.1 M). The chitosan solution, so obtained had a pH of about 5.0, was cooled down to around 4 C. Then 200 mg of BES in form of sodium salt was dissolved in 1.5 mL of cold water and added slowly to the cold chitosan solution under vigorous stirring. The pH of the resulting homogeneous and clear solution increases to about 7.17. This solution was disposed in a glass scintillation vial in the incubator at 37 C. Bulk gelation occurs in 10 minutes.
Experiment 2: gelation of coliagen/BES
Collagen was of the same origin (Example 1, Experiment 2). An
-17-aqueous solution of collagen (2% w/v) was prepared by dissolving 200 mg of collagen in 8.5 ml of an acetic acid solution with a pH about 3.6. Once a clear solution was obtained, it was cooled down to about 4 C, and then a cold solution of 200 mg of BES in 1.5 mL of water was added under continuous stirring. When the resulting neutral solution (pH - 7.2) appeared quite homogeneous and clear, it was poured in a Petri dish and placed at 37 C. A homogeneous uniform gel formed within 15 minutes.
Experiment 3: gelation of Chitosan-Collagen/BES
Collagen (100 mg) of the same origin (Example 1, Experiment 2) was first dissolved in 10 ml of an acetic acid solution (0.1 M). Then 100 mg of Chitosan was added to the resulting solution and stirred until all Chitosan was completely dissolved. After the whole system was cooled down to around 4 C, and 200 mg of BES in form of sodium salt dissolved in 1.5 ml of cold water, was added under continuous stirring. Once the solution was perfectly homogeneous and clear, the liquid mixture was poured in a Petri dish and placed at 37 C. The gel formed within 5 minutes.
Example 3 This example shows the typical experiments of acidic biopolymer solutions neutralized with tertiary hydroxyalkylamine, preferentially bis-[2-hydroxyethyl]iminotris [hydroxymethyl] methane (BIS-TRIS), and transformed to gel upon standing at 37 C.
Experiment 1: gelation of chitosan/BIS-TRIS
Chitosan solution with a pH around 5.0 was prepared by dissolving 200 mg of chitosan 85% deacetylated in 8.5 mL of aqueous HCI
solution (0.1M). This chitosan solution was cooled down to around 4 C, after which 400 mg of BIS-TRIS dissolved in 1.5 mL of cold water was added slowly to the cold chitosan solution under vigorous stirring. The pH
of the resulting homogeneous and clear solution increases to about 7.15.
This solution was disposed in a glass scintillation vial in the incubator at 37 C. Bulk gelation occurs within 10 minutes.
While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of
Experiment 3: gelation of Chitosan-Collagen/BES
Collagen (100 mg) of the same origin (Example 1, Experiment 2) was first dissolved in 10 ml of an acetic acid solution (0.1 M). Then 100 mg of Chitosan was added to the resulting solution and stirred until all Chitosan was completely dissolved. After the whole system was cooled down to around 4 C, and 200 mg of BES in form of sodium salt dissolved in 1.5 ml of cold water, was added under continuous stirring. Once the solution was perfectly homogeneous and clear, the liquid mixture was poured in a Petri dish and placed at 37 C. The gel formed within 5 minutes.
Example 3 This example shows the typical experiments of acidic biopolymer solutions neutralized with tertiary hydroxyalkylamine, preferentially bis-[2-hydroxyethyl]iminotris [hydroxymethyl] methane (BIS-TRIS), and transformed to gel upon standing at 37 C.
Experiment 1: gelation of chitosan/BIS-TRIS
Chitosan solution with a pH around 5.0 was prepared by dissolving 200 mg of chitosan 85% deacetylated in 8.5 mL of aqueous HCI
solution (0.1M). This chitosan solution was cooled down to around 4 C, after which 400 mg of BIS-TRIS dissolved in 1.5 mL of cold water was added slowly to the cold chitosan solution under vigorous stirring. The pH
of the resulting homogeneous and clear solution increases to about 7.15.
This solution was disposed in a glass scintillation vial in the incubator at 37 C. Bulk gelation occurs within 10 minutes.
While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of
-18-further modifications and this application is intended to cover any varia-tions, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth, and as follows in the scope of the appended claims.
Claims (40)
1. A polymeric liquid aqueous composition for producing self-gelling systems and gels, which comprises:
a) an acidic water-based medium;
b) 0.1 to 10% by weight of a pH-gelling acid-soluble polymer; and c) 0.1 to 10% by weight of a water-soluble molecule having a basic character and a pKa between 6.0 and 8.4, said water-soluble molecule being free of salt of polyol and sugar and wherein said water-soluble molecule is selected from the group consisting of N-[carbamoylmethyl]-2-aminoethane sulfonate (ACES), N,N-bis[2-hydroxyethyl]-2-aminoethane sulfonate (BES) and N,N-bis[hydroxyethyl]glycine (BICINE), and bis [2-hydroxyethyl]iminotris [hydroxymethyl]methane (BIS-TRIS);
wherein said liquid composition has a final pH ranging from 5.8 to 7.4, and forms a stable solid and homogeneous gel when heated within a temperature range from 10 to 70°C.
a) an acidic water-based medium;
b) 0.1 to 10% by weight of a pH-gelling acid-soluble polymer; and c) 0.1 to 10% by weight of a water-soluble molecule having a basic character and a pKa between 6.0 and 8.4, said water-soluble molecule being free of salt of polyol and sugar and wherein said water-soluble molecule is selected from the group consisting of N-[carbamoylmethyl]-2-aminoethane sulfonate (ACES), N,N-bis[2-hydroxyethyl]-2-aminoethane sulfonate (BES) and N,N-bis[hydroxyethyl]glycine (BICINE), and bis [2-hydroxyethyl]iminotris [hydroxymethyl]methane (BIS-TRIS);
wherein said liquid composition has a final pH ranging from 5.8 to 7.4, and forms a stable solid and homogeneous gel when heated within a temperature range from 10 to 70°C.
2. The composition according to claim 1, wherein said composition is prepared from at least one of organic and inorganic acid.
3. The composition according to claim 2, wherein the at least one of organic and inorganic acid is selected from the group consisting of hydrochloric acid, citric acid, ascorbic acid, lactic acid, lactobionic acid, acetic acid, salicylic acid, formic acid, glutamic acid, phosphoric acid, orthophosphoric acid, glycerophosphoric acid, and a mixture thereof.
4. The composition according to claim 1, wherein said polymer comprises a pH-gelling acid-soluble polysaccharide, polypeptidic or poly(amino acids), or synthetic polymer.
5. The composition according to claim 1, wherein said polymer comprises a solution of chitosan, modified chitosan or chitosan derivative, said solution of chitosan being cationic and bearing amino groups.
6. The composition according to claim 1, wherein said composition further comprises at least one other acid-soluble polymer.
7. The composition according to claim 6, wherein said at least one other polymer is selected from the group consisting of collagen, methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxyethyl propylcellulose, hydroxymethyl propyl cellulose, polyethylene oxide, polypropylene oxide, poly(ethylene oxide-co-propylene oxide) copolymers, poly(ethylene oxide-co-propylene oxide-co-ethylene oxide) copolymers, polyvinyl alcohol, a polycaprolactone diols, derivatives and mixtures thereof.
8. The composition according to claim 1, further comprising a solid particulate or a water-soluble additive.
9. The composition according to claim 1, further comprising a drug or a pharmaceutical agent.
10. The composition according to claim 1, further comprising microorganisms, plant cells, animal cells or human cells dispersed therein.
11. The composition according to claim 1, for use as a carrier for delivering a pharmaceutical agent in situ.
12. A method for preparing a composition according to claim 1, which comprises the steps of:
a) dissolving the pH-gelling acid-soluble polymer within an aqueous acidic solution of a pH from about 1.0 to about 5.0 to obtain an aqueous polymer composition having a concentration of 0.1 to 10%
by weight of said polymer;
b) dissolving 0.1 to 10% by weight of the water-soluble molecule having a basic character and a pKa between 6.0 and 8.4 within said aqueous polymer composition to obtain a clear liquid formulation with a pH ranging between 5.8 and 7.4, said water-soluble molecule being free of salt of polyol and sugar and wherein said water-soluble molecule is selected from the group consisting of N-[carbamoylmethyl]-2-aminoethane sulfonate (ACES), N,N-bis[2-hydroxyethyl]-2-aminoethane sulfonate (BES) and N,N-bis[hydroxyethyl]glycine (BICINE), bis [2-hydroxyethyl]iminotris [hydroxymethyl]methane (BIS-TRIS); and c) heating said liquid formulation at a temperature above 30°C to obtain a solid gel, said gel having a pH from about 5.8 to about 7.4.
a) dissolving the pH-gelling acid-soluble polymer within an aqueous acidic solution of a pH from about 1.0 to about 5.0 to obtain an aqueous polymer composition having a concentration of 0.1 to 10%
by weight of said polymer;
b) dissolving 0.1 to 10% by weight of the water-soluble molecule having a basic character and a pKa between 6.0 and 8.4 within said aqueous polymer composition to obtain a clear liquid formulation with a pH ranging between 5.8 and 7.4, said water-soluble molecule being free of salt of polyol and sugar and wherein said water-soluble molecule is selected from the group consisting of N-[carbamoylmethyl]-2-aminoethane sulfonate (ACES), N,N-bis[2-hydroxyethyl]-2-aminoethane sulfonate (BES) and N,N-bis[hydroxyethyl]glycine (BICINE), bis [2-hydroxyethyl]iminotris [hydroxymethyl]methane (BIS-TRIS); and c) heating said liquid formulation at a temperature above 30°C to obtain a solid gel, said gel having a pH from about 5.8 to about 7.4.
13. The method of claim 12, wherein said aqueous acidic solution is prepared from an organic or inorganic acid selected from the group consisting of acetic acid, ascorbic acid, glutamic acid, lactic acid, lactobionic acid, salicylic acid, phosphoric acid, hydrochloric acid, propionic acid, formic acid, and a mixture thereof.
14. The method of claim 12, wherein said polymer is a chitosan or a chitosan derivative, with a degree of deacetylation ranging from 35 to 99%.
15. The method of claim 12, wherein said aqueous polymer composition turns into a gel at a temperature above 10°C.
16. The method of claim 12, wherein said aqueous polymer composition turns into a gel at a temperature above 37°C.
17. The method of claim 12, wherein said polymer solution further comprises a solid particulate additive, said solid particulate additive being added to the polymer solution of step a) or b).
18. The method of claim 12, further comprising another acid-soluble polymer added to the polymer solution of step a) or b).
19. The method of claim 18, wherein said other polymer is selected from the group consisting of collagen, methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxyethyl propylcellulose, hydroxymethyl propyl cellulose, polyethylene oxide, polypropylene oxide, poly(ethylene oxide-co-propylene oxide) copolymers, poly(ethylene oxide-co-propylene oxide-co-ethylene oxide) copolymers, polyvinyl alcohol, polycaprolactone diols, and derivatives thereof.
20. The composition of any one of claims 1 to 11 for use in cosmetics, pharmacology, medicine or surgery.
21. The composition of any one of claims 1 to 11 for use into an implantable device or an implant for repair, reconstruction, or replacement of tissues or organs.
22. The composition of any one of claims 1 to 11 for use as an implantable, transdermal or dermatological drug delivery system.
23. The composition of any one of claims 1 to 11 for use as an opthalmological implant or a drug delivery system.
24. The composition of any one of claims 1 to 11 for use in cells-loaded artificial matrices for engineering and culture of bioengineered hybrid materials and tissue equivalents.
25. The composition of any one of claims 1 to 11, wherein said composition is loaded with cells selected from the group consisting of chondrocytes, fibrochondrocytes, ligament fibroblasts, skin fibroblasts, tenocytes, myofibroblasts, mesenchymal stem cells and keratinocytes.
26. The composition of claim 25 for use in culturing and engineering of artificial articular cartilage and cartilageous tissues and organs, either for surgical or laboratory testing applications.
27. The composition of claim 25 for use in processing and engineering of living artificial substitutes for ligaments, tendons, skin, bone, muscles and metabolic organs, either for surgical or laboratory testing applications.
28. The composition of claim 25 for use in living substitutes for the replacement of articular cartilages, fibrocartilages, cartilageous organs, ligaments, tendons, bone, tissues or skin.
29. The composition of claim 25 for use to induce an ectopic formation of fibrocartilage-like or cartilage-like tissues.
30. The composition of any one of claims 1 to 11 for use as an injectable or implantable gel biomaterial which acts as supports, carriers, reconstructive devices or substitutes for the formation in situ of bone-like, fibrocartilage-like or cartilage-like tissues.
31. Use of the composition according to any one of claims 1 to 11 in at least one of cosmetics, pharmacology, medicine and surgery.
32. Use of the composition according to any one of claims 1 to 11 into an implantable device or an implant for repair, reconstruction or replacement of tissues or organs.
33. Use of the composition according to any one of claims 1 to 11 as an implantable, transdermal or dermatological drug delivery system.
34. Use of the composition according to any one of claims 1 to 11 as an opthalmological implant or a drug delivery system.
35. Use of the composition according to any one of claims 1 to 11 in cells-loaded artificial matrices for engineering and culture of bioengineered hybrid materials and tissue equivalents.
36. Use of the composition of claim 25 in culturing and engineering of artificial articular cartilage and cartilageous tissues and organs, either for surgical or laboratory testing applications.
37. Use of the composition of claim 25 in processing and engineering of living artificial substitutes for ligaments, tendons, skin, bone, muscles and metabolic organs, either for surgical or laboratory testing applications.
38. Use of the composition of claim 25 in living substitutes for the replacement of articular cartilages, fibrocartilages, cartilageous organs, ligaments, tendons, bone, tissues or skin.
39. Use of the composition of claim 25 to induce an ectopic formation of fibrocartilage-like or cartilage-like tissues.
40. Use of the composition according to any one of claims 1 to 11 as an injectable or implantable gel biomaterial which acts as supports, carriers, reconstructive devices or substitutes for the formation in situ of bone-like, fibrocartilage-like or cartilage-like tissues.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16564199P | 1999-11-15 | 1999-11-15 | |
US60/165,641 | 1999-11-15 | ||
CA2427938A CA2427938C (en) | 1999-11-15 | 2000-11-10 | Novel temperature-controlled and ph-dependant self-gelling biopolymeric aqueous solution, composition and preparation thereof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2427938A Division CA2427938C (en) | 1999-11-15 | 2000-11-10 | Novel temperature-controlled and ph-dependant self-gelling biopolymeric aqueous solution, composition and preparation thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2685349A1 true CA2685349A1 (en) | 2001-05-25 |
CA2685349C CA2685349C (en) | 2013-09-17 |
Family
ID=22599806
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2685349A Expired - Lifetime CA2685349C (en) | 1999-11-15 | 2000-11-10 | Temperature-controlled and ph-dependant self-gelling biopolymeric aqueous solution |
CA2427938A Expired - Lifetime CA2427938C (en) | 1999-11-15 | 2000-11-10 | Novel temperature-controlled and ph-dependant self-gelling biopolymeric aqueous solution, composition and preparation thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2427938A Expired - Lifetime CA2427938C (en) | 1999-11-15 | 2000-11-10 | Novel temperature-controlled and ph-dependant self-gelling biopolymeric aqueous solution, composition and preparation thereof |
Country Status (7)
Country | Link |
---|---|
US (1) | US8920842B2 (en) |
EP (1) | EP1229940B1 (en) |
AU (1) | AU1375301A (en) |
CA (2) | CA2685349C (en) |
DK (1) | DK1229940T3 (en) |
ES (1) | ES2491866T3 (en) |
WO (1) | WO2001036000A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012024785A1 (en) * | 2010-08-27 | 2012-03-01 | Oligo Medic Inc. | Highly biocompatible dual thermogelling chitosan/glucosamine salt compositions |
US8506972B2 (en) | 2010-08-27 | 2013-08-13 | Oligo Medic Inc | Highly biocompatible dual thermogelling chitosan/glucosamine salt compositions |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2491866T3 (en) | 1999-11-15 | 2014-09-08 | Piramal Healthcare (Canada) Limited | Temperature-controlled, pH-dependent, self-gelling aqueous biopolymer solution |
AU1979201A (en) | 1999-12-09 | 2001-06-18 | Bio Syntech Canada Inc | Mineral-polymer hybrid composition |
US20030158302A1 (en) | 1999-12-09 | 2003-08-21 | Cyric Chaput | Mineral-polymer hybrid composition |
JP5089006B2 (en) * | 2000-06-29 | 2012-12-05 | ピラマル ヘルスケア (カナダ) リミテッド | Compositions and methods for repair and regeneration of cartilage and other tissues |
WO2002040072A2 (en) * | 2000-11-15 | 2002-05-23 | Bio Syntech Canada Inc. | Filler composition for soft tissue augmentation and reconstructive surgery |
US20040091540A1 (en) * | 2000-11-15 | 2004-05-13 | Desrosiers Eric Andre | Method for restoring a damaged or degenerated intervertebral disc |
US6989373B2 (en) * | 2000-11-15 | 2006-01-24 | Bio Syntech Canada Inc. | Method for restoring a fat-pad |
US7202091B2 (en) | 2001-04-11 | 2007-04-10 | Inlight Solutions, Inc. | Optically similar reference samples |
WO2004050100A1 (en) * | 2002-12-03 | 2004-06-17 | Bio Syntech Canada Inc. | Method for treating a tumor using a thermo-gelling chitosan composition |
GB2408937A (en) * | 2003-12-09 | 2005-06-15 | Johnson & Johnson Medical Ltd | pH dependent medicinal compositions |
GB0403938D0 (en) * | 2004-02-21 | 2004-03-24 | West Pharm Serv Drug Res Ltd | Chitosan containing solution |
US20090149421A1 (en) * | 2005-11-04 | 2009-06-11 | Bio Syntech Canada Inc. | Gel formation of polyelectrolyte aqueous solutions by thermally induced changes in ionization state |
DE602005016030D1 (en) | 2005-12-23 | 2009-09-24 | Medidom Lab | DUROPLASTIC NEUTRALIZED CHITOSAN COMPOSITION FOR FORMING A HYDROGEL, LYOPHILISATE, AND METHOD OF MANUFACTURING THEREOF |
PL3566713T3 (en) | 2009-03-10 | 2021-12-06 | Allergan Pharmaceuticals International Limited | Injectable biomaterials |
AU2011342287B2 (en) * | 2010-12-15 | 2015-09-17 | Greencentre Canada | Systems and methods for use of water with switchable ionic strength |
EP2794701B1 (en) | 2011-12-19 | 2017-03-08 | The University Of Sydney | A peptide-hydrogel composite |
US9688741B2 (en) | 2012-10-23 | 2017-06-27 | Elastagen Pty Ltd | Elastic hydrogel |
KR102239867B1 (en) | 2012-12-10 | 2021-04-13 | 앨러간 파마슈티컬스 인터내셔널 리미티드 | Scalable three-dimensional elastic construct manufacturing |
AU2014306362B2 (en) | 2013-08-13 | 2019-04-18 | Allergan Pharmaceuticals International Limited | Regeneration of damaged tissue |
JP6952348B2 (en) | 2015-07-24 | 2021-10-20 | トリンプ アイピー ピーティーワイ リミテッド | Sterilizing polymers and composites of polymers and cells and their synthesis |
JP6864001B2 (en) | 2015-11-03 | 2021-04-21 | ゾエティス・サービシーズ・エルエルシー | Sol-gel polymer compositions and their use |
US9655842B1 (en) | 2015-12-04 | 2017-05-23 | Covidien Lp | Injectable non-aqueous compositions and methods of treating vascular disease |
US11446324B2 (en) | 2017-04-20 | 2022-09-20 | Zoetis Services Llc | Veterinary compositions for use in treating mastitis, and associated methods |
CN111629766A (en) | 2017-12-01 | 2020-09-04 | 硕腾服务有限责任公司 | Hydrogel composition and use thereof |
CN109957150A (en) * | 2017-12-25 | 2019-07-02 | 成都昕才医药科技有限公司 | A kind of preparation method of temperature-sensitive hydrogel precursor |
CN109957116A (en) * | 2017-12-25 | 2019-07-02 | 成都昕才医药科技有限公司 | A kind of gel rubber material of phase transformation repeatedly |
CN109957115A (en) * | 2017-12-25 | 2019-07-02 | 成都昕才医药科技有限公司 | A kind of temperature-sensitive hydrogel |
CN108853599B (en) * | 2018-07-27 | 2021-03-05 | 王宇清 | Oxygen-enriched temperature-sensitive hydrogel and preparation method thereof |
CN110388199B (en) * | 2019-06-18 | 2021-06-01 | 中国石油天然气股份有限公司 | Large-discharge-capacity composite acid fracturing modification method for carbonate reservoir |
CN111603441B (en) * | 2020-07-01 | 2022-11-25 | 瑞希(重庆)生物科技有限公司 | Amphiphilic polyamino acid copolymer/poloxamer thermo-sensitive gel and preparation method thereof |
CN114349983A (en) * | 2022-01-10 | 2022-04-15 | 深圳市勇粒生物科技有限公司 | Anti-inflammatory and bactericidal amino acid hydrogel and preparation method and application thereof |
Family Cites Families (168)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2976574A (en) * | 1956-07-31 | 1961-03-28 | Union Carbide Corp | Chemical process and product |
US3266906A (en) * | 1962-12-13 | 1966-08-16 | Kelco Co | Algin gel and gelatin composition having high bloom strength and process |
US3586654A (en) * | 1969-04-15 | 1971-06-22 | Nat Distillers Chem Corp | Process for the preparation of polymer powders of controlled particle shape,size and size distribution and product |
US3755558A (en) * | 1971-02-23 | 1973-08-28 | Du Pont | Polylactide drug mixtures for topical application atelet aggregation |
IT1021282B (en) * | 1973-10-11 | 1978-01-30 | Basf Ag | PROCESS FOR THE PREPARATION OF POLYESTERIMIDE DISPERSIONS |
US4060081A (en) | 1975-07-15 | 1977-11-29 | Massachusetts Institute Of Technology | Multilayer membrane useful as synthetic skin |
US4185618A (en) * | 1976-01-05 | 1980-01-29 | Population Research, Inc. | Promotion of fibrous tissue growth in fallopian tubes for female sterilization |
US4097935A (en) * | 1976-07-21 | 1978-07-04 | Sterling Drug Inc. | Hydroxylapatite ceramic |
US4195175A (en) * | 1978-01-03 | 1980-03-25 | Johnson Edwin L | Process for the manufacture of chitosan |
US4337760A (en) * | 1978-10-13 | 1982-07-06 | Adolf Schwimmer | Method for the treatment of tumors with β-glucuronidase activity dependent pharmaceuticals |
JPS5943041B2 (en) * | 1979-02-16 | 1984-10-19 | 大日精化工業株式会社 | Sugar derivative having urea group and method for producing the same |
US4391909A (en) * | 1979-03-28 | 1983-07-05 | Damon Corporation | Microcapsules containing viable tissue cells |
US4254207A (en) * | 1979-12-26 | 1981-03-03 | Hercules Incorporated | Process for producing spherical particles or crystalline polymers |
US4933105A (en) * | 1980-06-13 | 1990-06-12 | Sandoz Pharm. Corp. | Process for preparation of microspheres |
DE3026762C2 (en) * | 1980-07-15 | 1985-04-25 | Akzo Gmbh, 5600 Wuppertal | Process for the production of porous, pulverulent polypropylene and use of the process products |
US4394373A (en) * | 1981-04-06 | 1983-07-19 | Malette William Graham | Method of achieving hemostasis |
US4532134A (en) * | 1981-04-06 | 1985-07-30 | Malette William Graham | Method of achieving hemostasis, inhibiting fibroplasia, and promoting tissue regeneration in a tissue wound |
US4424346A (en) * | 1981-06-04 | 1984-01-03 | Canadian Patents And Development Ltd. | Derivatives of chitins, chitosans and other polysaccharides |
SE441009B (en) * | 1982-03-08 | 1985-09-02 | Kjell Nilsson | WAY TO IMMOBILIZE LIVING BIOMATERIAL IN PEARLY POLYMERS |
US4605623A (en) * | 1982-11-08 | 1986-08-12 | Malette William Graham | Method of altering growth and development and suppressing contamination microorganisms in cell or tissue culture |
US4474769A (en) | 1983-05-13 | 1984-10-02 | Pfanstiehl Laboratories, Inc. | Chitosan as a contraceptive |
US4568559A (en) * | 1984-02-06 | 1986-02-04 | Biotek, Inc. | Composite core coated microparticles and process of preparing same |
US4659700A (en) * | 1984-03-02 | 1987-04-21 | Johnson & Johnson Products, Inc. | Chitosan-glycerol-water gel |
US4722948A (en) * | 1984-03-16 | 1988-02-02 | Dynatech Corporation | Bone replacement and repair putty material from unsaturated polyester resin and vinyl pyrrolidone |
US4731081A (en) * | 1984-09-11 | 1988-03-15 | Mentor Corporation | Rupture-resistant prosthesis with creasable shell and method of forming same |
US4902792A (en) * | 1985-04-19 | 1990-02-20 | Kanebo Ltd. | Fine cellulose particles and process for production thereof |
US4678470A (en) * | 1985-05-29 | 1987-07-07 | American Hospital Supply Corporation | Bone-grafting material |
US4895724A (en) * | 1985-06-07 | 1990-01-23 | Pfizer Inc. | Chitosan compositions for controlled and prolonged release of macromolecules |
JPS624702A (en) * | 1985-06-28 | 1987-01-10 | Lion Corp | Production of water-soluble acrylated chitosan |
US6005161A (en) | 1986-01-28 | 1999-12-21 | Thm Biomedical, Inc. | Method and device for reconstruction of articular cartilage |
US5902741A (en) * | 1986-04-18 | 1999-05-11 | Advanced Tissue Sciences, Inc. | Three-dimensional cartilage cultures |
US4877775A (en) | 1986-06-16 | 1989-10-31 | E. I. Du Pont De Nemours And Company | Polymeric aminosaccharides as antihypercholesterolemic agents |
US4803075A (en) * | 1986-06-25 | 1989-02-07 | Collagen Corporation | Injectable implant composition having improved intrudability |
US5989579A (en) * | 1986-10-02 | 1999-11-23 | Escalon Medical Corp. | Ocular insert with anchoring protrusions |
CA1340581C (en) * | 1986-11-20 | 1999-06-08 | Joseph P. Vacanti | Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices |
US5736372A (en) * | 1986-11-20 | 1998-04-07 | Massachusetts Institute Of Technology | Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure |
JPH01104305A (en) * | 1987-10-15 | 1989-04-21 | Tadashi Uragami | Membrane for separating liquid |
US4861627A (en) * | 1987-05-01 | 1989-08-29 | Massachusetts Institute Of Technology | Preparation of multiwall polymeric microcapsules |
EP0298501B1 (en) | 1987-07-10 | 1992-04-08 | Asahi Kogaku Kogyo Kabushiki Kaisha | Composition for forming calcium phosphate type hardening material and process for producing such hardening material |
US6610669B1 (en) | 1987-09-18 | 2003-08-26 | Genzyme Corporation | Water insoluble derivatives of polyanionic polysaccharides |
GB8803697D0 (en) * | 1988-02-17 | 1988-03-16 | Deltanine Research Ltd | Clinical developments using amniotic membrane cells |
JPH0228112A (en) * | 1988-04-21 | 1990-01-30 | Kaken Pharmaceut Co Ltd | Intraocular tension regulator for instillation |
US4956350A (en) | 1988-08-18 | 1990-09-11 | Minnesota Mining And Manufacturing Company | Wound filling compositions |
US5843156A (en) | 1988-08-24 | 1998-12-01 | Endoluminal Therapeutics, Inc. | Local polymeric gel cellular therapy |
US4938763B1 (en) * | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
US4911926A (en) * | 1988-11-16 | 1990-03-27 | Mediventures Inc. | Method and composition for reducing postsurgical adhesions |
US5126141A (en) * | 1988-11-16 | 1992-06-30 | Mediventures Incorporated | Composition and method for post-surgical adhesion reduction with thermo-irreversible gels of polyoxyalkylene polymers and ionic polysaccharides |
US5073202A (en) | 1989-03-09 | 1991-12-17 | Micro Vesicular Systems, Inc. | Method of using a biodegradable superabsorbing sponge |
US5324519A (en) * | 1989-07-24 | 1994-06-28 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
WO1991001720A1 (en) * | 1989-08-07 | 1991-02-21 | Herman Wade Schlameus | Composition and method of promoting hard tissue healing |
JPH0678372B2 (en) * | 1990-06-19 | 1994-10-05 | 信越化学工業株式会社 | Solution for preventing adhesion of polymer scale and method for preventing adhesion of polymer scale |
GB2246514B (en) | 1990-08-01 | 1993-12-15 | Scras | Sustained release pharmaceutical compositions and the preparation of particles for use therein |
US5071644A (en) | 1990-08-07 | 1991-12-10 | Mediventures, Inc. | Topical drug delivery with thermo-irreversible gels |
US5811094A (en) | 1990-11-16 | 1998-09-22 | Osiris Therapeutics, Inc. | Connective tissue regeneration using human mesenchymal stem cell preparations |
US5047055A (en) | 1990-12-21 | 1991-09-10 | Pfizer Hospital Products Group, Inc. | Hydrogel intervertebral disc nucleus |
US5226326A (en) * | 1991-05-31 | 1993-07-13 | Environmental Stress Screening Corp. | Vibration chamber |
WO1993000100A2 (en) * | 1991-06-24 | 1993-01-07 | Carrington Laboratories, Inc. | Wound cleanser |
US5318780A (en) | 1991-10-30 | 1994-06-07 | Mediventures Inc. | Medical uses of in situ formed gels |
GB2261672A (en) | 1991-11-18 | 1993-05-26 | Michael Braden | The use of biomaterials for tissue repair |
IL100096A (en) | 1991-11-20 | 1996-03-31 | Univ Ramot | Method for entrapment of active materials in chitosan |
US5658593A (en) * | 1992-01-16 | 1997-08-19 | Coletica | Injectable compositions containing collagen microcapsules |
US5306305A (en) * | 1992-01-31 | 1994-04-26 | Etex Corporation | Methods of coating implants with bony structure |
US5204382A (en) * | 1992-02-28 | 1993-04-20 | Collagen Corporation | Injectable ceramic compositions and methods for their preparation and use |
US5708152A (en) | 1992-03-27 | 1998-01-13 | Ciba Specialty Chemicals Corporation | N-substituted chitosan derivatives in a process for their preparation |
FR2692147B1 (en) | 1992-06-15 | 1995-02-24 | Centre Nat Rech Scient | Bioresorbable polymer microspheres free of surfactant, their preparation and their use as medicaments. |
US5266326A (en) | 1992-06-30 | 1993-11-30 | Pfizer Hospital Products Group, Inc. | In situ modification of alginate |
US5871985A (en) * | 1992-09-28 | 1999-02-16 | Brown University Research Foundation | Particulate non cross-linked chitosan core matrices for encapsulated cells |
US5709854A (en) * | 1993-04-30 | 1998-01-20 | Massachusetts Institute Of Technology | Tissue formation by injecting a cell-polymeric solution that gels in vivo |
GB9310030D0 (en) | 1993-05-15 | 1993-06-30 | Scras | Dry processed particles and process for the preparation of the same |
US5368051A (en) | 1993-06-30 | 1994-11-29 | Dunn; Allan R. | Method of regenerating articular cartilage |
CA2130295A1 (en) | 1993-08-26 | 1995-02-27 | Richard A. Berg | Ionically crosslinked glycosaminoglycan gels for soft tissue augmentation and drug delivery |
US5531716A (en) | 1993-09-29 | 1996-07-02 | Hercules Incorporated | Medical devices subject to triggered disintegration |
US6743783B1 (en) * | 1993-12-01 | 2004-06-01 | Marine Polymer Technologies, Inc. | Pharmaceutical compositions comprising poly-β-1→4-N-acetylglucosamine |
US5422116A (en) * | 1994-02-18 | 1995-06-06 | Ciba-Geigy Corporation | Liquid ophthalmic sustained release delivery system |
US6251137B1 (en) | 1994-03-23 | 2001-06-26 | Mcghan Medical Corporation | Synthetic triglyceride filler material for surgically implanted prostheses |
US5626861A (en) * | 1994-04-01 | 1997-05-06 | Massachusetts Institute Of Technology | Polymeric-hydroxyapatite bone composite |
US5723331A (en) * | 1994-05-05 | 1998-03-03 | Genzyme Corporation | Methods and compositions for the repair of articular cartilage defects in mammals |
DE69531638T2 (en) * | 1994-06-06 | 2004-06-17 | Osiris Therapeutics, Inc. | BIOMATRIX FOR TISSUE REGENATION |
EP0717630A1 (en) | 1994-07-08 | 1996-06-26 | SULZER Medizinaltechnik AG | Method of manufacturing implant materials |
AU3274895A (en) | 1994-07-18 | 1996-02-16 | Gel Sciences, Inc. | Novel polymer gel networks and methods of use |
SE9402531L (en) * | 1994-07-19 | 1996-01-20 | Medicarb Ab | wound healing agent |
SE9402528D0 (en) * | 1994-07-19 | 1994-07-19 | Astra Ab | Hard tissue stimulant with electricity |
US5510102A (en) | 1995-01-23 | 1996-04-23 | The Regents Of The University Of California | Plasma and polymer containing surgical hemostatic adhesives |
US5749874A (en) * | 1995-02-07 | 1998-05-12 | Matrix Biotechnologies, Inc. | Cartilage repair unit and method of assembling same |
US6080194A (en) * | 1995-02-10 | 2000-06-27 | The Hospital For Joint Disease Orthopaedic Institute | Multi-stage collagen-based template or implant for use in the repair of cartilage lesions |
US5906934A (en) * | 1995-03-14 | 1999-05-25 | Morphogen Pharmaceuticals, Inc. | Mesenchymal stem cells for cartilage repair |
NL9500580A (en) | 1995-03-27 | 1996-11-01 | Hollandse Signaalapparaten Bv | Phased array antenna equipped with a calibration network. |
US5620706A (en) * | 1995-04-10 | 1997-04-15 | Universite De Sherbrooke | Polyionic insoluble hydrogels comprising xanthan and chitosan |
US5676976A (en) | 1995-05-19 | 1997-10-14 | Etex Corporation | Synthesis of reactive amorphous calcium phosphates |
EP0830149A1 (en) | 1995-06-06 | 1998-03-25 | Osteogenics Inc. | Biocompatible hydroxyapatite formulations and uses therefor |
US5655546A (en) * | 1995-06-07 | 1997-08-12 | Halpern; Alan A. | Method for cartilage repair |
WO1996041818A1 (en) | 1995-06-09 | 1996-12-27 | Drohan William N | Chitin hydrogels, methods of their production and use |
JP3881707B2 (en) * | 1995-07-20 | 2007-02-14 | 学校法人松本歯科大学 | Method for producing osteogenesis promoter and method for producing osteogenic composition using osteogenesis promoter |
US5900238A (en) * | 1995-07-27 | 1999-05-04 | Immunex Corporation | Vaccine delivery system |
TW389694B (en) * | 1995-08-17 | 2000-05-11 | Novartis Ag | Compositions including o-carboxyalkyl chitosan and methods of use in ophthalmics |
WO1997017038A1 (en) | 1995-11-09 | 1997-05-15 | University Of Massachusetts | Tissue re-surfacing with hydrogel-cell compositions |
JP3781433B2 (en) * | 1995-11-16 | 2006-05-31 | ケース ウエスターン リザーブ ユニバーシティ | In vitro chondrogenesis induction of human mesenchymal stem cells |
JPH09143093A (en) | 1995-11-17 | 1997-06-03 | Hoechst Japan Ltd | Cartilage/bone-inductive restoring material |
PT1704878E (en) * | 1995-12-18 | 2013-07-17 | Angiodevice Internat Gmbh | Crosslinked polymer compositions and methods for their use |
US6200606B1 (en) * | 1996-01-16 | 2001-03-13 | Depuy Orthopaedics, Inc. | Isolation of precursor cells from hematopoietic and nonhematopoietic tissues and their use in vivo bone and cartilage regeneration |
US5842477A (en) | 1996-02-21 | 1998-12-01 | Advanced Tissue Sciences, Inc. | Method for repairing cartilage |
JP2000506182A (en) * | 1996-03-13 | 2000-05-23 | ラボラトワール・メルク・シヤルプ・エ・ドーム―シブレ・エス・エヌ・セー | Liquid-gel phase transition type eye drop composition |
CA2251129A1 (en) | 1996-05-03 | 1997-11-13 | Innogenetics N.V. | New medicaments containing gelatin cross-linked with oxidized polysaccharides |
IL118376A0 (en) * | 1996-05-22 | 1996-09-12 | Univ Ben Gurion | Polysaccharide sponges for cell culture and transplantation |
US5830503A (en) | 1996-06-21 | 1998-11-03 | Andrx Pharmaceuticals, Inc. | Enteric coated diltiazem once-a-day formulation |
US6060534A (en) * | 1996-07-11 | 2000-05-09 | Scimed Life Systems, Inc. | Medical devices comprising ionically and non-ionically crosslinked polymer hydrogels having improved mechanical properties |
US6649192B2 (en) | 1996-07-29 | 2003-11-18 | Universidade De Santiago De Compostela | Application of nanoparticles based on hydrophilic polymers as pharmaceutical forms |
US5964807A (en) | 1996-08-08 | 1999-10-12 | Trustees Of The University Of Pennsylvania | Compositions and methods for intervertebral disc reformation |
US7320962B2 (en) * | 1996-08-27 | 2008-01-22 | Baxter International Inc. | Hemoactive compositions and methods for their manufacture and use |
US6706690B2 (en) * | 1999-06-10 | 2004-03-16 | Baxter Healthcare Corporation | Hemoactive compositions and methods for their manufacture and use |
AU4941297A (en) | 1996-11-15 | 1998-06-10 | Dumex-Alpharma A/S | A method for promoting tissue repair |
JPH10158188A (en) * | 1996-11-29 | 1998-06-16 | Senju Pharmaceut Co Ltd | Composition for treating cornea |
US5866415A (en) * | 1997-03-25 | 1999-02-02 | Villeneuve; Peter E. | Materials for healing cartilage and bone defects |
WO1999004720A1 (en) | 1997-07-11 | 1999-02-04 | Reprogenesis Inc. | Repair of intervertebral disks |
CA2212300A1 (en) * | 1997-08-04 | 1999-02-04 | Abdellatif Chenite | In vitro or in vivo gelfying chitosan and therapeutic uses thereof |
US6110209A (en) | 1997-08-07 | 2000-08-29 | Stone; Kevin R. | Method and paste for articular cartilage transplantation |
US20020068048A1 (en) * | 1997-09-05 | 2002-06-06 | Patrick A. Dreyfus | Method for the treatment or diagnosis of human pathologies with disseminated or difficult to access cells or tissues |
US6417247B1 (en) * | 1997-10-14 | 2002-07-09 | Beth L. Armstrong | Polymer/ceramic composites |
CA2219399A1 (en) | 1997-10-24 | 1999-04-24 | Bio Syntech Ltd. | Bulk formation of monolithic polysaccharide-based hydrogels |
EP1030676B1 (en) | 1997-10-30 | 2005-09-14 | The General Hospital Corporation | Bonding of cartilaginous matrices using isolated chondrocytes |
US6482223B1 (en) | 1997-12-16 | 2002-11-19 | Closys Corporation | Clotting cascade initiating apparatus and methods of use |
JP2002507437A (en) | 1998-02-27 | 2002-03-12 | バイオエラスチックス・リサーチ・リミテッド | Injectable implant for tissue augmentation and recovery |
US6911212B2 (en) * | 1998-02-27 | 2005-06-28 | Musculoskeletal Transplant Foundation | Malleable putty and flowable paste with allograft bone having residual calcium for filling bone defects |
US7019192B2 (en) | 1998-02-27 | 2006-03-28 | Musculoskeletal Transplant Foundation | Composition for filling bone defects |
US7045141B2 (en) * | 1998-02-27 | 2006-05-16 | Musculoskeletal Transplant Foundation | Allograft bone composition having a gelatin binder |
DE19810965A1 (en) | 1998-03-13 | 1999-09-16 | Aventis Res & Tech Gmbh & Co | Nanoparticles comprising polyelectrolyte complex of polycation, polyanion and biologically active agent, especially useful for controlled drug release on oral administration |
US6179872B1 (en) * | 1998-03-17 | 2001-01-30 | Tissue Engineering | Biopolymer matt for use in tissue repair and reconstruction |
AU3097999A (en) | 1998-03-18 | 1999-10-11 | University Of Pittsburgh | Chitosan-based composite materials containing glycosaminoglycan for cartilage repair |
US20030147860A1 (en) | 2002-02-07 | 2003-08-07 | Marchosky J. Alexander | Compositions and methods for forming and strengthening bone |
DE19817698A1 (en) | 1998-04-22 | 1999-10-28 | Jan Zoellner | Composition used for flat disk implant, especially nucleus pulposus implant |
AU756785B2 (en) | 1998-07-13 | 2003-01-23 | University Of Southern California | Methods for accelerating bone and cartilage growth and repair |
HUP0105312A3 (en) | 1999-02-01 | 2003-12-29 | Genetics Inst Llc Cambridge | Methods and compositions for healing and repair of articular cartilage |
AU3699900A (en) | 1999-02-16 | 2000-09-04 | Sulzer Biologics, Inc. | Device and method for regeneration and repair of cartilage lesions |
US6436143B1 (en) | 1999-02-22 | 2002-08-20 | Anthony C. Ross | Method and apparatus for treating intervertebral disks |
CA2377435A1 (en) * | 1999-06-29 | 2001-01-04 | J. Alexander Marchosky | Compositions and methods for forming and strengthening bone |
US6429013B1 (en) | 1999-08-19 | 2002-08-06 | Artecel Science, Inc. | Use of adipose tissue-derived stromal cells for chondrocyte differentiation and cartilage repair |
ES2491866T3 (en) | 1999-11-15 | 2014-09-08 | Piramal Healthcare (Canada) Limited | Temperature-controlled, pH-dependent, self-gelling aqueous biopolymer solution |
US20030158302A1 (en) | 1999-12-09 | 2003-08-21 | Cyric Chaput | Mineral-polymer hybrid composition |
AU1979201A (en) | 1999-12-09 | 2001-06-18 | Bio Syntech Canada Inc | Mineral-polymer hybrid composition |
US20050244393A1 (en) | 1999-12-22 | 2005-11-03 | Henogen S.A. | Sealant or tissue generating product |
JP5089006B2 (en) * | 2000-06-29 | 2012-12-05 | ピラマル ヘルスケア (カナダ) リミテッド | Compositions and methods for repair and regeneration of cartilage and other tissues |
US6866866B1 (en) * | 2000-11-03 | 2005-03-15 | Andrx Labs, Llc | Controlled release metformin compositions |
US20040091540A1 (en) * | 2000-11-15 | 2004-05-13 | Desrosiers Eric Andre | Method for restoring a damaged or degenerated intervertebral disc |
US20040047892A1 (en) * | 2000-11-15 | 2004-03-11 | Desrosiers Eric Andre | Filler composition for soft tissue augmentation and reconstructive surgery |
US6756363B1 (en) * | 2000-11-17 | 2004-06-29 | Wound Healing Of Oklahoma, Inc. | Solutions and films of glycated chitosan |
US20060263401A1 (en) | 2001-07-13 | 2006-11-23 | Flow Focusing, Inc. | Formulation and Method for Preventing Infection |
KR100494265B1 (en) | 2001-08-14 | 2005-06-13 | 메디포스트(주) | Composition for treatment of articular cartilage damage |
US6632468B2 (en) * | 2001-08-16 | 2003-10-14 | Kerry Inc. | Controlled-viscosity food flavoring system |
US8740973B2 (en) | 2001-10-26 | 2014-06-03 | Icon Medical Corp. | Polymer biodegradable medical device |
DK1448607T3 (en) | 2001-11-15 | 2011-04-26 | Piramal Healthcare Canada Ltd | Composition and method for homogeneous modification or cross-linking of chitosan under neutral conditions |
PT1455802E (en) * | 2001-12-14 | 2008-11-03 | Dnp Canada Inc | Uses of chitosan oligosaccharides |
TWI245634B (en) * | 2001-12-28 | 2005-12-21 | Ind Tech Res Inst | Preparation of a biodegradable thermal-sensitive gel system |
US7514249B2 (en) | 2002-04-18 | 2009-04-07 | The University Of Florida Research Foundation, Inc. | Biomimetic organic/inorganic composites |
US20060204544A1 (en) | 2002-05-20 | 2006-09-14 | Musculoskeletal Transplant Foundation | Allograft bone composition having a gelatin binder |
DE60325742D1 (en) * | 2002-07-31 | 2009-02-26 | Alza Corp | INJECTABLE MULTIMODAL POLYMERS DEPOT COMPOSITIONS AND THEIR USES |
CA2494342A1 (en) * | 2002-07-31 | 2004-02-12 | Alza Corporation | Injectable depot compositions and uses thereof |
WO2004028578A1 (en) * | 2002-09-30 | 2004-04-08 | Regen Biotech, Inc. | Composition for stimulating bone-formation and bone consolidation |
NZ539810A (en) * | 2002-11-06 | 2008-03-28 | Alza Corp | Controlled release injectable depot formulations |
GB0302738D0 (en) | 2003-02-06 | 2003-03-12 | Advanced Biopolymers As | Composition |
US7217294B2 (en) * | 2003-08-20 | 2007-05-15 | Histogenics Corp. | Acellular matrix implants for treatment of articular cartilage, bone or osteochondral defects and injuries and method for use thereof |
GB0403938D0 (en) | 2004-02-21 | 2004-03-24 | West Pharm Serv Drug Res Ltd | Chitosan containing solution |
US20060004189A1 (en) * | 2004-07-02 | 2006-01-05 | James Gandy | Compositions for treating wounds and processes for their preparation |
US20060062768A1 (en) * | 2004-09-23 | 2006-03-23 | Olexander Hnojewyj | Biocompatible hydrogel compositions |
ITRM20040539A1 (en) * | 2004-11-02 | 2005-02-02 | Mavi Sud S R L | PREPARE WITH CHITIN OR ITS DERIVATIVES FOR COSMETIC OR MEDICAL USE. |
WO2007127795A2 (en) | 2006-04-25 | 2007-11-08 | Bumgardner Joel D | Chitosan/nanocrystalline hydroxyapatite composite microsphere-based scaffolds |
EP2094283A4 (en) | 2006-11-30 | 2010-09-01 | Biosyntech Canada Inc | Method for in situ solidification of blood-polymer compositions for regenerative medicine and cartilage repair applications |
US8153612B2 (en) * | 2006-12-11 | 2012-04-10 | Chi2Gel Ltd. | Injectable chitosan mixtures forming hydrogels |
US7776840B2 (en) | 2007-02-21 | 2010-08-17 | Cutanea Life Sciences, Inc. | Methods of use of biomaterial and injectable implant containing biomaterial |
-
2000
- 2000-11-10 ES ES00975711.3T patent/ES2491866T3/en not_active Expired - Lifetime
- 2000-11-10 CA CA2685349A patent/CA2685349C/en not_active Expired - Lifetime
- 2000-11-10 DK DK00975711.3T patent/DK1229940T3/en active
- 2000-11-10 CA CA2427938A patent/CA2427938C/en not_active Expired - Lifetime
- 2000-11-10 EP EP00975711.3A patent/EP1229940B1/en not_active Expired - Lifetime
- 2000-11-10 AU AU13753/01A patent/AU1375301A/en not_active Abandoned
- 2000-11-10 WO PCT/CA2000/001341 patent/WO2001036000A1/en active Application Filing
-
2009
- 2009-10-09 US US12/576,354 patent/US8920842B2/en not_active Expired - Fee Related
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012024785A1 (en) * | 2010-08-27 | 2012-03-01 | Oligo Medic Inc. | Highly biocompatible dual thermogelling chitosan/glucosamine salt compositions |
CN103189435A (en) * | 2010-08-27 | 2013-07-03 | 奥利高医疗公司 | Highly biocompatible dual thermogelling chitosan/glucosamine salt compositions |
US8506972B2 (en) | 2010-08-27 | 2013-08-13 | Oligo Medic Inc | Highly biocompatible dual thermogelling chitosan/glucosamine salt compositions |
US8784850B2 (en) | 2010-08-27 | 2014-07-22 | Oligo Médic Inc. | Highly biocompatible dual thermogelling chitosan/glucosamine salt composition |
AU2011293055B2 (en) * | 2010-08-27 | 2016-01-07 | Oligo Medic Inc. | Highly biocompatible dual thermogelling chitosan/glucosamine salt compositions |
CN103189435B (en) * | 2010-08-27 | 2016-02-17 | 奥利高医疗公司 | The dual Thermogelling chitosan/glucosamine salt composition of high degree of biocompatibility |
EA024569B1 (en) * | 2010-08-27 | 2016-09-30 | Олиго Медик Инк. | Highly biocompatible dual thermogelling chitosan/glucosamine salt compositions |
Also Published As
Publication number | Publication date |
---|---|
CA2685349C (en) | 2013-09-17 |
US20100028434A1 (en) | 2010-02-04 |
AU1375301A (en) | 2001-05-30 |
ES2491866T3 (en) | 2014-09-08 |
WO2001036000A1 (en) | 2001-05-25 |
CA2427938C (en) | 2010-02-16 |
CA2427938A1 (en) | 2001-05-25 |
US8920842B2 (en) | 2014-12-30 |
EP1229940A1 (en) | 2002-08-14 |
EP1229940B1 (en) | 2014-05-14 |
DK1229940T3 (en) | 2014-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8920842B2 (en) | Temperature controlled and pH dependent self gelling biopolymeric aqueous solution | |
AU724878B2 (en) | Temperature-controlled pH-dependant formation of ionic polysaccharide gels | |
Li et al. | Thermo-sensitive injectable glycol chitosan-based hydrogel for treatment of degenerative disc disease | |
US20040047892A1 (en) | Filler composition for soft tissue augmentation and reconstructive surgery | |
KR102275105B1 (en) | High Density Reticulated Cross-linked Hyaluronic Acid and Process for Preparing the Same | |
Moura et al. | In situ forming chitosan hydrogels prepared via ionic/covalent co-cross-linking | |
KR101400907B1 (en) | Filler composition for tissue augmentation | |
Zhao et al. | Ultra-tough injectable cytocompatible hydrogel for 3D cell culture and cartilage repair | |
Arakawa et al. | Polymer design and development | |
Madl et al. | Injectable cucurbit [8] uril-based supramolecular gelatin hydrogels for cell encapsulation | |
CN109575315B (en) | PVA supramolecular hydrogel and preparation method and application thereof | |
CN113454166A (en) | Hydrogel compositions based on polysaccharides and zwitterionic polymers and methods of use thereof | |
Li et al. | Smart collagen hydrogels based on 1-Ethyl-3-methylimidazolium acetate and microbial transglutaminase for potential applications in tissue engineering and cancer therapy | |
Phan et al. | Development of bioresorbable smart injectable hydrogels based on thermo-responsive copolymer integrated bovine serum albumin bioconjugates for accelerated healing of excisional wounds | |
Ishikawa et al. | On-demand retrieval of cells three-dimensionally seeded in injectable thioester-based hydrogels | |
US20120020932A1 (en) | Thermosensitive hydrogel composition and method | |
Yuan et al. | Thermosensitive hydrogel for cartilage regeneration via synergistic delivery of SDF-1α like polypeptides and kartogenin | |
WO2002040072A2 (en) | Filler composition for soft tissue augmentation and reconstructive surgery | |
CA2299687C (en) | Temperature-controlled ph-dependant formation of ionic polysaccharide gels | |
RU2641053C1 (en) | Solid phase method for production of bioactive composite for tissue growing based on hyaluronic acid or polylactide microparticles and its copolymers, and method for manufacture of implant based on this composite | |
ES2906715T3 (en) | Biomaterial devices for guided tissue regeneration | |
CA2913405A1 (en) | Compositions comprising a polymer-protein conjugate and an environmentally-responsive polymer and uses thereof | |
Yuan et al. | A facile bioorthogonal chemistry-based reversible to irreversible strategy to surmount the dilemma between injectability and stability of hyaluronic acid hydrogels | |
Thakur et al. | Protein-based gels: preparation, characterizations, applications in drug delivery, and tissue engineering | |
DE102015000363A1 (en) | New modular functionalizable peptide hydrogels |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDC | Discontinued application reinstated | ||
MKEX | Expiry |
Effective date: 20201110 |